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ABSTRACT OF THE DISSERTATION  
Mechanisms of Protective Activity of West Nile Virus Anti-Envelope Antibodies 
In vitro and In vivo 
by 
Matthew Raymond Vogt 
Doctor of Philosophy in Biology and Biomedical Sciences 
Immunology 
Washington University in St. Louis, 2013 
Professor Michael S. Diamond, Chairperson 
 
West Nile virus (WNV) is a neurotropic flavivirus capable of causing severe 
disease and death in humans. Studies in mice have demonstrated that the humoral 
immune response against WNV limits primary infection and protects against a secondary 
challenge. Accordingly, passive transfer of immune serum or monoclonal antibodies 
(MAb) against the envelope (E) protein either prior to WNV infection or shortly 
thereafter is sufficient to protect mice from disease. The E protein is an immunodominant 
antigen in the antibody response to WNV infection, and the most potent neutralizing 
MAbs recognize an epitope on the lateral ridge of domain III (DIII-LR) of the E protein. 
However, studies with serum from human patients show that antibodies against the DIII-
LR epitope comprise at best, a minor component of the human anti-WNV antibody 
response. Rather, the human anti-E protein response is more dominantly directed against 
an epitope on the fusion loop of domain II (DII-FL), and antibodies against this epitope 
neutralize infection poorly in vitro. The studies described in this thesis examined how the 
antibody response to WNV is protective despite being skewed away from the most 
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potently neutralizing epitope (DIII-LR). In the first section, two WNV-specific human 
MAbs that were isolated from B cell populations of convalescent patients that strongly 
neutralized WNV infection in vitro and protected mice against lethal infection in vivo 
were characterized in detail. The MAbs were localized to E protein epitopes that are 
present only on intact WNV virions and subviral particles, and neutralization of infection 
occurred through a viral fusion blockade mechanism, similar to DIII-LR MAbs. This 
suggests that WNV infection may indeed induce strongly neutralizing antibodies, which 
simply go undetected by current epitope-specific diagnostics that utilize recombinant, 
monomeric E protein. Subsequently, a DII-FL mouse MAb that was non-neutralizing in 
vitro was shown to protect mice from WNV infection in vivo via its Fc effector functions, 
requiring C1q, Fc-gamma receptor III (CD16), and phagocytic cells. This highlights the 
limitations of current in vitro surrogate markers of protection, which cannot account for 
the beneficial effects conferred by immunodominant DII-FL antibodies. Overall, these 
studies provide an enhanced understanding of the mechanisms of protection of the human 
anti-WNV antibody response. 
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Chapter I 
 
Introduction 
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West Nile virus disease. West Nile virus (WNV) is a mosquito-borne flavivirus that is 
capable of infecting humans and causing severe disease and even death. WNV belongs to 
the Flavivirus genus within the Flaviviridae family. Other members of this genus that 
cause significant human disease include St. Louis encephalitis (SLEV) and Japanese 
encephalitis (JEV) viruses, which are grouped into the JEV serocomplex along with 
WNV, as well as dengue (DENV), yellow fever (YFV), and tick-borne encephalitis 
(TBEV) viruses (reviewed in (55, 56)). 
WNV cycles in nature between several species of birds and mosquitoes, with 
humans and other mammals as dead-end hosts (36, 77). Most human infections are 
asymptomatic, but ~20% result in a mild febrile illness. Less than one percent of 
infections cause severe neuroinvasive disease, which can produce neurologic sequelae 
lasting for months to years, and even death (24, 88, 89). Risk factors for symptomatic 
infection and disease include an age of greater than 55 years, a compromised immune 
status, genetic variation in the OAS1 gene, and a CC5Δ32 genotype (25, 32, 53, 54). 
There is currently no approved vaccine or therapy for WNV infection, although both are 
being actively developed (4). 
WNV first appeared in the Western hemisphere in 1999 in New York and spread 
rapidly through North America, with thousands of severe human cases annually in the 
United States. Curiously, though, few human cases have been reported in Latin America 
despite the migration of avian hosts and appropriate vectors for transmission (47, 76). 
WNV also cycles endemically in the “Old World” of Central Europe, the Middle East, 
and Northern Africa (83). 
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Flavivirus infection. The flavivirus life cycle begins with binding to poorly 
characterized cell surface receptors. Upon binding, internalization of flaviviruses is 
believed to occur through receptor-mediated, clathrin-dependent endocytosis (1, 101, 
102). After trafficking to Rab5+ and/or Rab7+ endosomes (48, 101), the mildly acidic pH 
within the lumen induces structural alterations in the flavivirus E protein (13, 62), which 
includes changes in its oligomeric state (13, 62, 92). During this process, also known as 
type II fusion, the hydrophobic peptide on the fusion loop of domain II of the E protein 
inserts into the endosomal membrane, thus physically joining the host and viral 
membranes, which allows the infectious RNA genome to enter the cytoplasm (44, 45). 
Flaviviruses have a ~11 kilobase, positive polarity, single-stranded RNA genome. 
Upon release into the cytoplasm, the genome is translated as a single polypeptide, which 
is then cleaved by host and viral proteases into three structural (capsid [C], pre-membrane 
[prM], and envelope [E]) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, 
NS4B, and NS5) proteins (reviewed in (55, 56)). The production of nonstructural proteins 
allows for creation of negative sense RNA copies of the genome, each of which can serve 
as a template for the replication of multiple copies of positive sense genomes. These 
nascent genomes can either serve as template for translation or be packaged into progeny 
virions (15).   
After translation of input strand RNA and viral replication, progeny virion 
assembly occurs within the endoplasmic reticulum (ER), with the capsid protein and 
genomic RNA in the cytoplasm associating with prM and E proteins in the lumen (55). 
Virus particles bud into the lumen of ER as immature virions (106). Transit of the 
immature virion through the mildly acidic compartments of the trans-Golgi network 
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(TGN) increases the susceptibility of prM to cleavage by a furin-like serine protease (52, 
104). Release of prM is required for optimal infectivity (38) and completes the 
maturation process, occurring upon secretion of the virion into the neutral pH of the 
extracellular space (104). While cleavage of prM is a required step in the viral lifecycle, 
it can be an inefficient process in some cell types. Moreover, partially mature flavivirus 
virions containing some uncleaved prM also retain infectivity (37, 68). Adding even 
further complexity, the E protein rearrangements of maturation can nucleate from more 
than one point, creating multiple structural protein environments within a single virion 
(80). 
 
E protein structure. X-ray crystallography studies have elucidated the three-domain 
structure of the flavivirus E protein (40, 61, 63, 72, 84, 108). Domain I (DI) is a central, 
eight-stranded β-barrel, which contains the only N-linked glycosylation site in WNV E. 
Domain II (DII) is a long, finger-like protrusion from DI and contains the highly 
conserved fusion peptide at its distal end. Domain III (DIII) adopts an immunoglobulin-
like fold at the opposite end of DI, and is believed to contain a putative site for receptor 
attachment (9, 19, 50). 
 The hinge region between DI and DII is highly flexible, as the angle between 
these domains on DENV E rotates 27º during the transition from the immature to mature 
state (108). The hinge then rotates back 30º during the pre- to post-fusion domain 
rearrangement (13, 62, 67). Two x-ray crystal structures of similarly prepared WNV E 
protein also have distinct DI-DII hinge angles, differing by 5º (40, 72). Similarly, the 
position of DIII in relation to DI changes markedly during the fusion process. This is 
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necessary for the E protein to transition from a dimer, in which the fusion peptide is 
buried in the area between DI and DIII of its dimeric partner (61, 63, 84, 108), to a 
trimer, in which the fusion peptides of the three E proteins are grouped in an exposed 
conformation at the tip of the trimeric spike for insertion into the host endosomal 
membrane (13, 62, 67). 
 
Virion structure. The mature flavivirus virion has a ~500Å diameter and consists of a 
single RNA genome surrounded by capsid protein, a lipid bilayer, and a shell of prM/M 
and E proteins (41-43, 65). In immature virions, three pairs of E and prM interact as 
trimers and form sixty heterotrimeric spiked projections with icosahedral symmetry (106, 
107). In this formation, prM covers the hydrophobic fusion peptide and prevents 
adventitious insertion into host membranes during exocytosis (52, 104). As the immature 
virion traffics through the mildly acidic TGN, a dramatic rearrangement of the prM-E 
spikes occurs on the virion surface. This low pH induced transition causes the E proteins 
on immature virions to lie flat as antiparallel dimers on the surface of the virion (49), 
which allows for prM cleavage (52, 104). Mature flavivirus virions are covered by 90 
anti-parallel E protein homodimers, which are arranged flat along the surface in a 
herringbone pattern with T=3 quasi-icosahedral symmetry (49, 65, 105).  
The 180 E proteins on the surface of the mature virion exist in one of three 
different environments: the 2-, 3-, and 5-fold axes of symmetry (65). This is important in 
the context of antibody binding because, while one face of the E protein generally faces 
toward the virion membrane and the other outward, some epitopes are surface exposed 
only along certain axes of symmetry (42, 43, 57) or in certain states of maturation (18). 
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For example, the lateral ridge of DIII (DIII-LR) epitope is obscured at the 5-fold axis of 
symmetry, so a DIII-LR specific antibody can only bind to 120 of the 180 copies of E per 
virion (42, 71). 
Similar to the maturation process, large rearrangements of the E proteins on the 
virion surface are required for fusion of the virion membrane to the host endosomal 
membrane. Lowered pH in the late endosome causes E protein dimers to dissociate and 
lift off of the surface of the virion (41), allowing fusion peptide insertion into the host 
membrane and E trimerization (13, 62, 67). It is hypothesized that the C-terminal stem-
loop structures of the E protein then “zipper up” along the length of DII, pulling the spike 
back toward the surface of the virion and drawing the membrane of the endosome in 
proximity with the virion membrane. Apposition of the fusion loop and transmembrane 
domain of the E protein presumably causes the two membranes to fuse, completing the 
class II fusion process (62). 
 
Anti-E antibodies. Studies in mice and other animals have established that humoral 
immunity is an essential component of the protective host response against flaviviruses, 
including WNV (reviewed in (78, 85)). B cells and secreted antibody were necessary for 
survival of mice after WNV inoculation (26, 27), and passive transfer of WNV-immune 
serum protected naive recipients from WNV challenge (28, 97). Moreover, pre-exposure 
prophylaxis and post-exposure therapy with WNV-specific monoclonal (MAb) or 
polyclonal antibodies conferred protection in both mice and hamsters (6, 7, 28, 64, 73, 
95, 97, 99). Antibody neutralization can occur by blocking attachment to host cells, entry 
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of virions into cells, or the low pH-dependent fusion of the viral and host cell membranes 
(78). 
The E protein of WNV is the principal target of neutralizing antibodies, although 
antibodies are also elicited against prM, NS1, NS3, and NS5 proteins (20, 100). Studies 
by several groups have shown that neutralization of WNV can occur after antibodies bind 
to a series of discrete epitopes on all three domains of the E protein (5, 23, 35, 73, 75, 
86). The generation of large panels of mouse and human MAbs against epitopes spanning 
the WNV E protein has enhanced our understanding of the antibody response to WNV. 
The most potently neutralizing anti-WNV MAbs localize to the DIII-LR epitope. One 
well-characterized strongly neutralizing DIII-LR mouse MAb, E16, blocks infection 
primarily at a post-attachment step (71) and requires engagement of only a fraction of its 
epitopes on the surface of the virion (79). E16 acts by sterically hindering DIII from 
rotating over DI during the pH dependent fusion event in the late endosome (42, 98). 
While studies in WNV emphasize the potent neutralization potential of MAbs that bind to 
DIII-LR, studies with DENV have demonstrated the strong neutralization potential of 
MAbs that bind to additional DIII epitopes (14, 90, 93, 94).  
Studies with anti-flavivirus MAbs have highlighted two other important 
functional aspects of antibodies: cross-reactivity and maturation sensitivity. MAbs 
directed against DIII-LR epitopes are specific to the virus they were generated against, 
and often even to the genotype within the specific species of flavivirus used for 
immunization (5, 14, 73, 86, 90, 93, 94). DIII-LR MAbs also equivalently neutralize 
WNV preparations that are fully mature, fully immature, and those with a mixture of 
maturity (68). Conversely, MAbs raised against the fusion loop of DII (DII-FL) are 
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generally cross-reactive amongst flaviviruses (21, 23, 34, 75), presumably due to the 
highly conserved amino acid sequence of this epitope, which is responsible for insertion 
into the host endosomal membrane during fusion (13, 62, 67). DII-FL MAbs can 
neutralize partially mature WNV but are unable to neutralize completely mature virus, 
which likely accounts for the fraction of virions resistant to neutralization by DII-FL 
MAbs when standard preparations of virus with mixed maturity are tested (68). 
Studies of the human antibody response to WNV infection reveal that, in contrast 
to mice, antibodies that bind the DIII-LR epitope comprise a minor component of the 
humoral response in most individuals (74). Rather, the human anti-E repertoire appears to 
be skewed toward the DII-FL epitope in WNV and many flaviviruses (22, 74, 91, 99), 
which is somewhat surprising given that MAbs recognizing this epitope neutralize WNV 
poorly (75) and do not neutralize fully mature virus (68). However, the ability of DII-FL 
antibodies to cross-react against other flaviviruses (21, 23, 34, 75) could benefit people 
living in areas where multiple flaviviruses co-circulate by preventing heterologous 
infection. 
 
Fc effector functions. Antibody neutralization of viruses is traditionally thought of as the 
ability to prevent infection by physically impeding either attachment or entry into cells 
(78). However, during infection in vivo the effector functions of the crystallizable 
fragment (Fc) of antibodies, specifically the ability to bind to complement (17) and Fc-γ 
receptors (70, 81), also can contribute to the protective effects of antibodies. Multiple 
experimental approaches have demonstrated the importance of Fc effector functions to 
antibody protection in vivo (8, 39, 60, 103). Several studies have compared protection by 
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MAb or polyclonal antibodies and lack of protection by the corresponding F(ab’)2 
fragment(s) to conclude that Fc effector functions mediate protection (3, 11, 12, 35, 51, 
58, 66). The conclusions of these comparisons have limitations because F(ab’)2 fragments 
are not recirculated by the neonatal Fc receptor (FcRn) and therefore have a much shorter 
half-life than antibodies in vivo. One study did control for F(ab’)2 recirculation effects by 
pre-adsorbing YFV with equimolar amounts of neutralizing MAb 2E10 or F(ab’)2, which 
was equally potent in vitro, then infecting mice intracerebrally. Higher mortality in 
F(ab’)2 treated mice at many concentrations tested suggested that the Fc portion of 2E10 
was important for its protective effects in vivo (87). 
Specific isotypes and subclasses of antibody are more effective at engaging Fc 
effector molecules. In this thesis, most studies are performed with IgG MAbs or purified 
polyclonal IgG, so this isotype will be the focus of the following material. In general, IgG 
must be bound to its cognate antigen to enable activation of Fc effector functions (31, 46, 
69). Also, IgG molecules contain a single N-linked glycosylation on each heavy chain 
that is necessary for binding to both C1q and Fc-γ receptors (FcγR) (96).  
 C1q is the complement protein responsible for activation of the classical cascade 
of complement. When C1q binds to two or more IgG molecules that are bound to their 
antigen, a cascade of serine proteases are activated. C1r cleaves C1s, which then cleaves 
C2 and C4 into two fragments each. Combined, the C4b2a molecule forms the classical 
C3 convertase. This cleaves C3 molecules, causing a release of the C3a anaphylotoxin 
and covalent attachment of the C3b opsonin onto the virion surface, activating the 
immune system and marking the virion for phagocytosis, respectively (reviewed in (82)). 
Opsonization of antigens with C3b also increases activation of the humoral immune 
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response via complement receptors CD21 (CR2) and CD35 (CR1) by enhancing antigen 
presentation on macrophages and dendritic cells and dramatically lowering the threshold 
of activation for B cells (16). Other complement molecules, such as mannose binding 
lectin (MBL), can engage antigen-bound IgG and initiate the complement cascade via 
C1q independent bypass pathways (2). Generally, human IgG3 > IgG1 >> IgG2 (10) and  
mouse IgG2b > IgG2a = IgG2c > IgG3 > IgG1 (33) at binding to C1q, although some 
murine IgG1 molecules can fix complement while others cannot (29, 30). 
 In vitro studies have demonstrated the ability of C1q to enhance the neutralizing 
effects of MAbs. Comparing the addition of serum from wild type and C1q-/- mice or by 
adding purified C1q to neutralization assays demonstrated the ability of C1q to reduce the 
50% effective concentration (EC50) of various anti-WNV MAbs. The use of MAb E16 
with an A330L mutation in the heavy chain, which abolished C1q binding, confirmed the 
shift in EC50 was C1q dependent. This effect was due to cross linking of antibodies on the 
virion surface, which decreased the amount of MAb required for neutralization (59). In 
related studies, in vitro neutralization by the anti-vaccinia virus MAb B126 was only 
detectable upon the addition of purified C1q. The importance of complement for the 
function of B126 was highlighted in vivo, as it prevented weight loss in vaccinia 
challenged mice, but this effect was diminished in mice depleted of complement activity 
by treatment with cobra venom factor (8). 
 The other major Fc effector mechanism of IgG is the engagement of FcγRs, which 
can be activating (FcγRI, CD64; FcγRIII, CD16; FcγRIV) and inhibitory (FcγRIIb, 
CD32). Generally, FcγRI > FcγRIV > FcγRIIb ≈ FcγRIII in their affinity for IgG 
molecules, although different FcγRs bind preferentially to different antibody isotypes 
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(70). Activating FcγRs are expressed on the surface of cells, and most associate with an 
intracellular signaling molecule, the common gamma chain of activating FcγRs (FcRγ). 
All activating FcγR intracellular signaling occurs via immunoreceptor tyrosine-based 
activation motifs (ITAMs). Various immune cell types express different combinations of 
activating FcγRs, and concordantly ligation of these FcγRs can trigger many effects: 
phagocytosis of immune complexes, antibody dependent cellular cytotoxicity (ADCC), 
and downstream signaling that activates cells or stimulates the production and release of 
cytokines. The inhibitory FcγRIIb is a transmembrane molecule with an intracellular 
immunoreceptor tyrosine-based inhibitory motif (ITIM), which is mainly responsible for 
tempering the immune response in states of high activation, especially by increasing the 
activation threshold in B cells to prevent the overproduction of antibodies (reviewed in 
(81)). 
Previous studies have implicated FcγRs as crucial to in vivo protection by 
antiviral MAbs. Three non-neutralizing MAbs individually reduced murid herpesvirus 4 
titers in the lungs of wild type but not FcγR-/- mice, which lacked both activating and 
inhibitory FcγR (103). An L234A, L235A variant of the neutralizing anti-human 
immunodeficiency virus (HIV) b12 MAb, which cannot bind to FcγRs or C1q, could not 
suppress chimeric simian immunodeficiency virus-HIV plasma titers in macaques as 
effectively as wild type b12. However, a K322A variant of b12, which lacks binding to 
C1q but retains FcγR binding, reduced titers similarly to wild type b12, indicating a 
requirement of FcγR engagement for this protective activity (39). Pre-treatment of mice 
with neutralizing MAb 667 against a different retrovirus, a variant of the Friend murine 
leukemia virus, enhanced many aspects of the adaptive immune response to infection. 
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Dendritic cell uptake of antibody-virion immune complexes was inhibited by an  FcγR 
blocking MAb as well as the use of F(ab’)2 fragments rather than MAb to create immune 
complexes prior to infection (eliminating concerns of lack of recirculation by FcRn) (60). 
 
Rationale. The studies described in this thesis examined how the antibody response to 
WNV is protective despite being skewed away from the most potently neutralizing 
epitope (DIII-LR) toward a poorly neutralizing epitope (DII-FL). The first section 
addresses the hypothesis that WNV infection may indeed induce strongly neutralizing 
antibodies that simply go undetected by current epitope-specific diagnostics, which 
utilize recombinant E proteins. For these studies, two WNV-specific human MAbs that 
were isolated from B cell populations of convalescent patients were characterized in 
detail. These MAbs were initially identified as being able to bind WNV virions and 
subviral particles but not recombinant E protein, yet they strongly neutralized WNV 
infection in vitro and protected mice against lethal infection in vivo. This indicated their 
potential for revealing previously unappreciated epitopes on the virion.  
Given the rapid spread of WNV throughout the United States and into Canada, it 
was surprising that so few human cases have been reported in Latin America. One 
hypothesis for this discrepancy was that the high prevalence of DENV infections and 
frequency of YFV vaccination in this region may result in “susceptible” individuals 
having poorly-neutralizing cross-reactive antibodies against WNV that are not detected 
by standard neutralization assays. However, poorly neutralizing mouse MAbs had been 
shown to protect mice from WNV infection in vivo, a phenomenon that also had been 
demonstrated in several other in vivo models of virus infection. Therefore, the second 
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part of this thesis was aimed at determining whether poorly neutralizing MAbs and 
polyclonal antibodies protect against WNV in vivo, and if so whether this was due to 
their Fc effector functions. 
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INTRODUCTION 
 West Nile encephalitis virus (WNV) is a positive polarity single-stranded RNA 
virus of the Flavivirus genus within the Flaviviridae family. Other members of this genus 
that cause significant human disease include dengue (DENV), St. Louis encephalitis 
(SLEV), Japanese encephalitis (JEV), yellow fever (YFV), and tick-borne encephalitis 
(TBEV) viruses. Flaviviruses are translated as a single polypeptide, which is then cleaved 
by host and viral proteases into three structural (capsid [C], pre-membrane [prM], and 
envelope [E]) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 
proteins (reviewed in (42, 43)).  
 WNV cycles in nature between several species of birds and Culex mosquitoes, 
with humans and other mammals as dead-end hosts (25, 62). Infection causes syndromes 
ranging from a mild febrile illness to severe encephalitis and death (13, 72). WNV has 
spread globally and causes outbreaks with thousands of severe human cases annually in 
the United States. Age greater than 55, a compromised immune status, and a CC5Δ32 
genotype have been associated with more severe disease (15, 20). There is currently no 
approved vaccine or therapy for WNV infection.  
 The mature WNV virion has a ~500Å diameter and consists of a single RNA 
genome surrounded by capsid protein, a lipid bilayer, and a shell of prM/M and E 
proteins (31, 55). X-ray crystallography studies have elucidated the three-domain 
structure of the flavivirus E protein (30, 48, 50, 58, 67). Domain I (DI) is a central, eight-
stranded β-barrel, which contains the only N-linked glycosylation site in WNV E. 
Domain II (DII) is a long, finger-like protrusion from DI and contains the highly 
conserved fusion peptide at its distal end. Domain III (DIII) adopts an immunoglobulin-
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like fold at the opposite end of DI, and is believed to contain a putative site for receptor 
attachment (6, 8, 40).  
 Within an infected cell, progeny WNV are assembled initially as immature 
particles. In immature virions, three pairs of E and prM interact as trimers and form sixty 
spiked projections with icosahedral symmetry (85, 86). Exposure to mildly acidic 
conditions in the trans-Golgi secretory pathway promotes virus maturation through a 
structural rearrangement of the E proteins and cleavage of prM to M by a furin-like 
protease (41, 83). Mature WNV virions are covered by 90 anti-parallel E protein 
homodimers, which are arranged flat along the surface in a herringbone pattern with 
quasi-icosahedral symmetry (55).  
Upon binding to poorly characterized cell surface receptors, internalization of 
WNV is believed to occur through receptor-mediated, clathrin-dependent endocytosis (1, 
79, 80). After trafficking to Rab5- and/or Rab7-positive endosomes (38, 79), the mildly 
acidic pH within the lumen of the endosome induces structural alterations in the 
flavivirus E protein (7, 49), which includes changes in its oligomeric state (7, 49, 77). 
During this process, also known as type II fusion, the hydrophobic peptide on the fusion 
loop of domain II of the E protein inserts into the endosomal membrane, thus physically 
joining the host and viral membranes, which allows the infectious RNA genome to enter 
the cytoplasm (32, 33). 
 Humoral immunity is an essential component of the protective host response 
against flaviviruses, including WNV (reviewed in (64, 68)). Studies by several groups 
have shown that neutralization of WNV can occur after antibodies bind to a series of 
discrete epitopes on all three domains of the E protein (3, 12, 22, 59, 61, 71). To date, the 
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most potently neutralizing MAbs localize to an epitope on the lateral ridge of DIII (DIII-
lr). One well-characterized strongly neutralizing mouse MAb, E16, blocks infection 
primarily at a post-attachment step (57) and requires engagement of only a fraction of its 
epitopes on the surface of the virion (66). Studies of the human antibody response to 
WNV infection reveal that, in contrast to mice, antibodies that bind the DIII-lr epitope 
comprise a minor component of the neutralizing humoral response in most individuals 
(60). 
 In this study, we characterized two strongly neutralizing novel human MAbs 
(CR4348 and CR4354) that were selected from an antibody phage display library 
constructed from B cells of subjects that survived WNV infection (78). We demonstrate 
that both MAbs are WNV-specific, bind weakly to recombinant or yeast surface-
displayed E proteins, exhibit pH-sensitive binding to viral particles, and protect against 
lethal infection in mice. Our experiments suggest these human MAbs map to distinct 
epitopes and neutralize infection at a post-attachment stage, likely by inhibiting the acid-
catalyzed viral fusion step.  
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MATERIALS AND METHODS 
Preparation of virus, subviral particles, and pyrene-labeled virus. WNV strain 
3000.0259, which was isolated in New York in 2000 (16), was used to generate stocks of 
passage 2 (4.2 x 107 PFU/ml) and passage 3 (2.0 x 107 PFU/ml) virus after propagation in 
C6/36 Aedes albopictus cells. The propagation of wild type and mutant WNV from the 
New York 1999 (NY99ic) infectious clone (5) are detailed below. WNV subviral 
particles (SVP) were generated after transfection of BHK21-15 cells with a pcDNA3.1 
plasmid expressing premembrane (prM) and envelope (E) genes (36) from the NY99 
WNV strain using FuGENE HD (Roche) according to the manufacturer’s instructions. 
Supernatants containing SVP were collected 48 hours after transfection, filtered through a 
0.2 μm filter, and stored aliquotted at -80ºC.  
Labeling of WNV with the fluorescent probe pyrene was performed essentially as 
described for alphaviruses (73, 81). Briefly, BHK21-15 cells cultured in the presence of 
15 μg/ml of 16-(1-pyrenyl)-hexadecanoic acid (Invitrogen) were infected with WNV at 
an MOI of 4. At 24 hours post-infection, the medium was harvested, clarified by low-
speed centrifugation and pyrene-labeled WNV particles were pelleted by 
ultracentrifugation in a Beckman type 19 rotor for 15 hours at 48,500 x g at 4°C. The 
virus particles were further purified on an Optiprep (Axis-Shield) density (15-55% w/v) 
gradient by ultracentrifugation in a Beckman SW41 rotor for 18 hours at 100,000 x g at 
4°C. The infectious titer was determined by TCID50 analysis and the protein 
concentration was measured by micro-Lowry analysis. 
Monoclonal antibodies (MAbs). Unless otherwise specified, all antibodies used 
were protein A-purified and of the human IgG1 subclass. Humanized E16 (Hu-E16) was 
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generated from a mouse MAb after genetic engineering as described previously (59). 
CR4348, CR4354, and CR4293 (anti-prM) were selected from scFv-phage display 
libraries constructed from peripheral blood lymphocytes isolated from three human 
patients who survived neuroinvasive WNV disease (78). Construction of the libraries, 
selections with the libraries and reformatting of scFv-phage into full-length IgG1 
molecules has been previously described in detail (78). WNV E24 (mouse IgG2a) 
localizes to the DIII-lr epitope (59) and was purified by protein A affinity 
chromatography. Control non-WNV reactive anti-FITC and anti-DENV1 E50 human 
IgG1 were gifts of S. Johnson (Macrogenics, Rockville, MD).  
Neutralization assays. (a) Plaque Reduction Neutralization Test (PRNT). In many 
experiments, the neutralizing activity of MAbs was determined using a PRNT50 analysis. 
Briefly, serially diluted MAbs were mixed 1:1 with 102 PFU of WNV in Dulbecco’s 
Modified Eagle Medium (DMEM) containing 10% FBS (Omega Scientific) and 
incubated one hour at 37ºC. The WNV-MAb mixture was then added to individual wells 
of a 6-well tissue culture plate in duplicate or triplicate with either Vero or BHK21-15 
cells. Viral adsorption proceeded for one hour at 37ºC, followed by an overlay with 1% 
low-melt agarose (SeaPlaque) in α-MEM and 4% FBS. After solidification, plaques were 
visualized three to four days later following fixation with 2 ml of 10% formaldehyde, 
removal of agarose plugs, and staining with 1% (w/v) crystal violet in 20% (v/v) ethanol. 
Plaques were counted and then normalized to the average of six control wells in which 
WNV was mixed with DMEM containing 10% FBS and no antibody. 
(b) Pre- and post-attachment neutralization assays. To assay for post-attachment 
neutralization, a PRNT assay was completed essentially as above with the following 
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modifications. All solutions and Vero cells were pre-chilled to 4ºC, then 102 PFU of 
WNV was added to each well of cells and viral adsorption allowed for one hour at 4ºC.  
Wells were then washed thrice with media, and MAb at the specified concentrations was 
added. Virion-antibody complexes were allowed to form for one hour at 4ºC followed by 
three washes with chilled media. Cells were then warmed to 37ºC and the PRNT assay 
was completed as described above. In parallel, a PRNT assay with all cells and solutions 
at 4ºC was performed in which MAb and WNV were mixed for one hour at 4ºC prior to 
addition to cells (pre-attachment assay). 
 (c) Reporter Virus Particle (RVP) Assay. WNV and mutant RVP were generated 
as described previously (65, 66). Separate plasmids expressing the wild type prM-E genes 
and the capsid (C) gene of WNV were transfected into a BHK cell that stably propagates 
a WNV replicon expressing GFP. In some experiments, the prM-E plasmid was mutated 
using the QuikChange site directed mutagenesis kit (Stratagene) to introduce specific 
amino acid substitutions. In other experiments, RVP were produced from 293T cells at 
various stages of maturation (immature, partially mature, or fully mature) according to 
published protocols (56). Supernatants containing RVP were harvested 48 hours after 
transfection, filtered through a 0.2 μm filter, and stored aliquotted at -80ºC. RVP were 
incubated with serial dilutions of MAb under conditions of antibody excess at room 
temperature (RT) for one hour. Subsequently, MAb-RVP mixtures were added to Raji-
DCSIGNR cells, which stably express the DC-SIGNR attachment factor (14), and were 
incubated at 37ºC for 48 hours. Infected cells were assayed for GFP expression using a 
BD FACSArray flow cytometer. Alternatively human CD32A (Fc-γRIIA) expressing 
K562 cells were used to assay for antibody dependent enhancement of infection. 
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Yeast surface display of WNV E proteins. The generation of yeast that express 
the WNV E protein ectodomain (amino acid residues 1-415) or DIII (residues 296-415) 
has been described previously (59). Yeast expressing WNV E or DIII were washed in 
PBS, 2% BSA, and 0.025% NaN3, incubated with primary MAbs (50 μg/ml) for 30 
minutes on ice, washed thrice, mixed with a 1:500 dilution of AlexaFluor 647 conjugated 
goat anti-human antibody (Molecular Probes), washed again, and processed on a BD 
FACSArray flow cytometer. 
Antigen capture and solid-phase ELISA. Nunc MaxiSorp polystyrene 96-well 
plates were either coated overnight at 4ºC with murine DIII-lr MAb (10 μg/ml) or for one 
hour at 37ºC with soluble recombinant WNV E protein ectodomain (10 µg/ml, generated 
as described in (57)) in a pH 9.3 carbonate buffer. Plates were washed thrice in ELISA 
wash buffer (PBS with 0.02% Tween 20) and blocked for one hour at 37ºC with ELISA 
block buffer (PBS, 2% bovine serum albumin, and 0.02% Tween 20). On plates coated 
with murine DIII-lr MAb, SVP or WNV infectious virions (wild type or mutant) were 
captured for one hour at RT. Subsequently, plates were rinsed five times in wash buffer 
and then incubated with anti-WNV or control human IgG1 (10 µg/ml in block buffer) in 
triplicate for one hour at RT. Plates were washed five times and then incubated with 
biotinylated rabbit anti-human IgG antibody (1:1250 dilution, Southern Biotech) for one 
hour at RT in blocking buffer. Plates were washed again five times and then sequentially 
incubated with 2 μg/ml of horseradish peroxidase conjugated streptavidin (Vector 
Laboratories) and tetramethylbenzidine (TMB) substrate (Dako). The reaction was 
stopped with 2N H2SO4 and emission (450 nm) was read on an iMark microplate reader 
(BIORAD). In the pH-dependent ELISA, plates were washed four times with wash buffer 
 38 
and once with indicated pH buffer (150 mM NaCl, 0.05% Tween 20, 50 mM MES [pH 
6.0] or wash buffer [pH 7.4]) after trapping of SVP. The plate was incubated for 30 
minutes at RT with indicated pH buffer, and then washed five times in wash buffer 
followed by normal completion of capture ELISA protocol. 
Western blots. Recombinant WNV E protein, SVP, or infectious WNV was 
diluted in 2X SDS loading buffer with or without β-mercaptoethanol (5% v/v) and 
incubated at RT or 95ºC for 10 minutes as indicated.  Samples were loaded into wells of a 
NuPAGE (Invitrogen) 4-12% Bis-Tris gradient gel and electrophoresed. Protein was 
transferred to a polyvinylidene fluoride (PVDF) transfer membrane using the iBlot 
system (Invitrogen).  Membranes were rinsed in PBS, 0.05% Tween 20 (wash buffer) 
while gently shaking for 10 minutes at RT, then blocked overnight with block buffer (5% 
dry milk in wash buffer) shaking at RT. After five 10 minute washes, membranes were 
stained with primary human MAb (1 μg/ml diluted in block buffer with normal goat 
serum added at 1:250 dilution) for one hour at RT. After five additional washes, 
membranes were incubated with horseradish peroxidase conjugated goat anti-human 
antibody (Sigma, diluted 1:5000 in block buffer) for one hour. Membranes were then 
washed five times for 10 minutes in wash buffer and developed using ECL reagent 
(Amersham).   
Generation of neutralization escape mutants. WNV was incubated with 25 
μg/ml of CR4348 or CR4354 for one hour at RT in DMEM. The mixture was added to 
Vero cells in a 6 well plate at a multiplicity of infection (MOI) of 1. After infection for 2 
hours at 37ºC, wells were washed thrice with DMEM and fresh media containing 25 
μg/ml of MAb was added. Virus growth under antibody selection was allowed for 48 
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hours at 37 ºC. At each passage, half of the supernatant was mixed 1:1 with a 50 µg/ml of 
MAb for one hour. The remaining half of the supernatant was aliquotted and stored at -
80ºC. After three passages under MAb selection, virus-containing supernatants were 
tested by PRNT for escape from neutralization by CR4348 or CR4354. After 
confirmation of the escape phenotype, an aliquot of the supernatant was used in a Vero 
cell plaque assay under MAb selection. Plaques were visualized by overlaying with 
neutral red and sterile glass Pasteur pipettes were used to isolate resistant virus from 
single plaques. Plaque-purified virus was amplified under MAb selection (25 μg/ml) 
overnight at 37ºC. Vero cells were scraped from wells and total cellular RNA isolated 
using an RNEasy kit (Qiagen). cDNA was amplified using a reverse primer (2501R: 5'- 
TGCCGGCTGATGTCTATGG -3') in the WNV NS1 gene, and served as a template for 
polymerase chain reaction (PCR) amplification of the prM and E genes using forward 
(454F: 5'-AGCGTAGGAGCAGTTACCC-3') and the 2501R reverse primers. The prM 
and E genes were then directly sequenced from gel purified PCR products and the 
neutralization escape mutant sequence was compared to the sequence of the laboratory 
stock WNV that was passaged and plaque-purified in parallel in the absence of MAb 
selection. 
WNV infectious cDNA clone and mutant generation. The two plasmid WNV 
NY99 cDNA clone (36) was used to create wild type and mutant infectious WNV. Single 
amino acid substitutions were introduced into the pWNAB plasmid by site directed 
mutagenesis. Wild type and mutant pWNAB (encoding nucleotides 1-2495 of the WNV 
genome) and wild type pWNCG (nucleotides 2495-11,029) plasmids were grown in 
SURE-2 supercompetent E. coli (Stratagene) at RT.  Each plasmid was digested with 
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XbaI and NgoMIV restriction endonucleases and the resultant ~5.2 and 8 kilobase 
fragments of pWNAB and pWNCG, respectively, were gel purified and ligated with T4 
DNA ligase (Invitrogen) at 4ºC overnight. The reactions were then heat-inactivated, 
digested with XbaI to linearize the DNA, treated with proteinase K, extracted twice with 
a phenol and chloroform, and precipitated with ethanol at -20ºC overnight. All DNA was 
used as a template for in vitro DNA-dependent RNA transcription with the AmpliScribe 
T7 kit (Epicentre) with the addition of m7G(5')ppp(5')A cap analog (New England 
BioLabs). Transcription reactions were run at 37ºC for 5 hours and the reaction was then 
electroporated (3 pulses at 850V, 25μF, ∞Ω) into BHK21-15 cells.  Cells were added to a 
T75 tissue culture flask in DMEM with 10% FBS and observed for the onset of 
cytopathic effects (CPE). Once CPE were observed, virus-containing supernatant was 
collected, cellular debris pelleted, and supernatant aliquots frozen at -80ºC.  The cells 
remaining in the T75 were harvested and used as a source of viral RNA to confirm that 
the desired mutant sequence was retained. 
Structural Analysis. The coordinates for the WNV E protein (RCSB accession 
number 2HG0) were divided by domains and fit onto the cryoelectron microscopy 
structure for the mature Dengue virus (RCSB accession number 1K4R) using CCP4MG 
to create a model of the WNV E protein dimer. Distances were calculated and figures 
prepared using PyMol (http://www.pymol.org). 
Mouse experiments. Mouse studies were approved and performed according to 
the guidelines of the Washington University School of Medicine Animal Safety 
Committee. Three to four week-old outbred NIH Swiss mice (Harlan) were infected by 
intraperitoneal (IP) injection with WNV NY99ic diluted in Hank’s Balanced Salt 
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Solution containing 1% heat-inactivated FBS. For antibody protection studies, one day 
prior to infection mice were treated by IP injection with 50 μg of indicated MAb or 
vehicle control diluted in 100 μl PBS. Mice were monitored daily for 21 days for 
mortality and were euthanized when moribund. In some experiments, passive transfer of 
MAbs was performed with five week-old C57BL/6 mice (Jackson Laboratories) as 
described previously (59). 
Fusion assay. Fusion of pyrene-labeled WNV with liposomes was monitored 
continuously in a Fluorolog 3-22 fluorometer (BFi Optilas), at excitation and emission 
wavelengths of 345 nm and 475 nm, respectively. Liposomes (large unilamellar vesicles 
with a diameter of ~200 nm) were prepared by a freeze/thaw-extrusion procedure as 
described previously (73). Liposomes consisted of a mixture of phosphatidylcholine (PC) 
from egg yolk, phosphatidylethanolamine (PE) prepared by transphosphatidylation of egg 
PC, and cholesterol in a molar ratio of 1:1:2. The lipids were obtained from Avanti Polar 
Lipids. The concentration of phospholipids was determined by phosphate analysis.  
Pyrene-labeled WNV (1.24 μg of total viral protein) and liposomes (final 
concentration, 200 μM phospholipid) were mixed in a final volume of 665 µl in 5 mM 
Hepes, 150 mM NaCl, 0.1 mM EDTA, pH 7.4 (HNE) under continuous stirring in a 
temperature-controlled cuvette at 37°C. At t = 0 seconds, the medium was acidified by 
addition of 35 µl 0.1 MES, 0.2 M acetic acid, pre-titrated with NaOH to achieve the final 
desired pH. The fusion scale was calibrated such that 0% fusion corresponded to the 
initial excimer fluorescence value. The 100% value was obtained through the addition of 
35 µl 0.4 M octaethyleneglycol monododecyl ether (Fluka Chemie AG) to achieve an 
infinite dilution of the probe. The extent of fusion was determined 60 seconds after 
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acidification. To determine the influence of the MAbs on membrane fusion, pyrene-
labeled WNV was incubated with different concentrations of MAbs for one hour at RT 
prior to mixing with liposomes. 
Statistical Analysis. All data were analyzed using Prism software (GraphPad 
Prism, San Diego, CA). Kaplan-Meier survival curves were analyzed by the log-rank test. 
For neutralization assays an unpaired student’s T-test was used to determine significance. 
For ELISA data a paired student’s T-test was used to determine significance. 
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RESULTS 
 Characterization of strongly neutralizing human MAbs. Previous studies that 
mapped the epitope specificity of inhibitory antibodies in convalescent human serum 
suggested that only a fraction of WNV-infected patients developed antibodies against the 
strongly neutralizing epitope on DIII-lr of the E protein (60). Consistent with this, few 
DIII-specific human MAbs were isolated from phage display single chain variable 
fragment (scFv) libraries from infected patients (78) and none were selected from very 
large libraries of pooled uninfected donors (22). As human convalescent serum retains 
strong neutralizing activity, we hypothesized that antibodies with distinct specificities 
must contribute to the inhibitory activity.  
Antibody-phage display libraries constructed from peripheral blood lymphocytes 
of three convalescent patients after WNV infection were screened for reactivity on WNV 
antigen as described previously (78). All selected monoclonal phage specifically bound a 
preparation of inactivated WNV and immobilized prM-E containing subviral particles 
(SVP). SVP, in addition to containing prM/M proteins, display 60 E protein homodimers 
in a lipid bilayer (18) whereas virions have 90 E protein homodimers in a distinct 
icosahedral arrangement (39, 55). Two MAbs, CR4348 and CR4354, which demonstrated 
strong neutralizing activity in pilot functional assays, tested negative for binding to 
recombinant E protein by ELISA (data not shown); in contrast, other neutralizing human 
MAbs that were identified in the screen and previously characterized (e.g., CR4374 (60, 
78)) readily bound recombinant E protein.  
In both plaque reduction (PRNT) and WNV reporter virus particle (RVP) assays 
CR4348 (PRNT50 = 536 ng/ml; RVP EC50 = 146 ng/ml) and CR4354 (PRNT50 = 88 
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ng/ml; RVP EC50 = 26 ng/ml) inhibited infection strongly, albeit slightly less than that 
achieved with a humanized version of a therapeutic WNV type-specific mouse MAb, E16 
(Hu-E16) that maps to the DIII-lr epitope (59) (Fig 1A and 1B). CR4348 and CR4354 
appeared distinct from Hu-E16 as they did not efficiently recognize the ectodomain of E 
protein when expressed as purified protein or displayed on the surface of yeast (Fig 2A 
and 2B). These neutralizing human MAbs also efficiently neutralized variant WNV RVP 
composed of E proteins encoding a T332K mutation that abrogates neutralization of 
virtually all DIII-lr MAbs (Fig 1C and (3, 59)). Additionally, both human MAbs likely 
do not recognize linear epitopes as they did not identify prM, M, or E by Western blot 
under reducing or non-reducing conditions (Fig 2C).  
Because CR4348 and CR4354 neutralized WNV but did not appear to recognize 
recombinant E protein, we speculated they might inhibit infection by binding to an 
epitope on prM that was not be detected by Western blot. To test this, we took advantage 
of a series of WNV RVP preparations that differ with respect to the efficiency of the 
maturation process; similar preparations were used previously to define differential 
neutralizing activity of anti-WNV MAbs generated in mice (56). WNV RVPs were 
produced as fully mature (in cells over-expressing the furin protease), partially and 
heterogeneously mature (standard conditions) or largely immature (in the presence of 
NH4Cl, which inhibits furin cleavage). These three types of RVP differ in their content of 
prM ranging from virtually none (mature) to >95% (immature). CR4348 and CR4354 
neutralized prM-containing or absent particles equivalently (Fig 3), eliminating the pr 
peptide as part of the epitope for either MAb. 
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 An alternative possibility was that CR4348 and CR4354 do not bind a viral 
protein but instead inhibit WNV infection by binding a host cell surface receptor and 
blocking attachment and/or entry. However, if the neutralizing MAbs CR4348 and 
CR4354 recognized a structural protein on the virion, they should enhance infection in 
Fc-γ receptor expressing cells when the stoichiometry of binding falls below the 
neutralization threshold (51, 66). Addition of sub-neutralizing concentrations of CR4348 
and CR4354 to K562 cells that display human CD32 (Fc-γRIIA) enhanced infection in a 
manner that was analogous to that observed with Hu-E16 (Fig 1D). This experiment 
suggests that CR4348 and CR4354 recognized a protein on the surface of the infectious 
virion. 
 To corroborate these findings, we used a capture ELISA to measure direct binding 
of CR4348 and CR4354 to SVP and infectious WNV virions. Notably, CR4348 and 
CR4354 bound both to SVP and infectious virus (Fig 2D, P < 0.002). However, CR4348 
and CR4354 did not bind to DENV particles, consistent with their inability to neutralize 
these viruses in a plaque reduction assay (data not shown). Thus, the biochemical and 
functional analyses suggested that CR4348 and CR4354 neutralize WNV by virtue of 
their ability to bind an epitope on one of the viral structural proteins (M or E) that 
requires a specific oligomeric arrangement present on the virions or SVP. 
Neutralization by CR4348 and CR4354 occurs primarily at a post-attachment 
step. Antibody neutralization of enveloped viruses may occur by inhibiting receptor 
attachment, internalization, and/or endosomal fusion (63, 88). To determine the stage of 
the viral entry pathway at which CR4348 and CR4354 inhibit infection, we performed 
pre- and post-attachment neutralization assays (11, 29, 57). CR4348 and CR4354 were 
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incubated with WNV before or after virus binding to a monolayer of Vero cells and 
infection was measured by a plaque reduction assay. As expected, CR4348 and CR4354 
efficiently neutralized infection when pre-mixed with virus (Fig 4A). Both MAbs also 
inhibited WNV infection when added after virus adsorption to the cell surface, indicating 
that at least part of their neutralizing activity was at a post-attachment step of the viral life 
cycle. When added after attachment, CR4354 was more potent than CR4348 in 
neutralizing infection. Importantly, no pre- or post-attachment neutralization was 
detected with a non-binding isotype control, and a largely post-attachment pattern of 
inhibition was seen with Hu-E16 (Fig 4A) as observed previously (57). 
pH sensitivity of CR4348 and CR4354 binding.  Exposure of flavivirus virions or 
SVP to acidic pH in solution or in the endosome prompts a rapid structural rearrangement 
(7, 19, 49, 77). Given that CR4348 and CR4354 preferentially recognize epitopes present 
on virions and SVP, but not on recombinant E proteins (Fig 2), we hypothesized that 
changes in the oligomeric arrangement of E that are associated with shifts in pH might 
alter immunoreactivity. To test this, we used our SVP capture ELISA, exposing particles 
to different pH (6.0 or 7.4) conditions for 30 minutes prior to pH normalization (pH 7.4) 
and incubation with MAbs. Notably, our control neutralizing MAb, Hu-E16, did not 
show pH-sensitive binding (Fig 4B). In contrast, exposure of SVP to pH 6.0, which 
should promote E protein rearrangement and irreversible trimer formation, significantly 
reduced binding of both CR4348 and CR4354 (P < 0.003).  
CR4348 and CR4354 inhibit WNV fusion. Since both CR4348 and CR4354 have 
the capacity to neutralize WNV infection at a post-attachment step, we investigated 
whether these mAbs would also affect WNV fusion. To evaluate this, we utilized a model 
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liposome fusion assay with pyrene-labeled virus that has been previously used to monitor 
the fusion dynamics of TBEV (9, 19, 75-77). Briefly, pyrene-labeled WNV was pre-
incubated with different concentrations of MAbs for one hour at room temperature and 
then mixed with liposomes at 37°C. Fusion was triggered by acidification of the mixture 
to pH 6.3, which is the optimal pH for WNV fusion (B. Moesker, J. Wilschut and J. Smit, 
unpublished observations). In the absence of antibodies or in the presence of 50 nM (7.5 
μg/ml) of a non-binding control MAb, fusion was essentially complete within seconds 
upon acidification. In contrast, pre-incubation of the virus with CR4348 or CR4354 
potently inhibited fusion activity (Fig 4C). Both MAbs reduced the extent of fusion in a 
dose-dependent manner (Fig 4D). CR4354 inhibited fusion at concentrations of 1 nM (or 
0.15 μg/ml) and above, whereas for CR4348 a minimal concentration of 10 nM (or 1.5 
μg/ml) was required. This difference in potency was also reflected in the maximum level 
of fusion inhibition at saturating antibody concentrations. CR4354 and CR4348 
neutralized ~85% and ~65% of the virus particles, respectively (Fig 4D). Thus, in the 
model liposome assay, CR4348 and CR4354 can block low-pH-catalyzed fusion of the 
majority of WNV virions; this supports the idea that these MAbs act at a post-attachment 
step. Nonetheless, even under saturating antibody concentrations, a fraction of the virus 
particles resists complete inhibition by these MAbs, although the rate of fusion of the 
residual fractions are substantially lower than in the absence of antibody. 
Generation of neutralization escape mutants. Because CR4348 and CR4354 
recognized a determinant on the WNV virion or SVP, which is not readily apparent on 
recombinant or yeast displayed forms of E, we generated neutralization escape mutants to 
further define their epitopes. After three sequential virus passages on Vero cells under 
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CR4348 or CR4354 selection (25 μg/ml), WNV was no longer neutralized by these 
MAbs in plaque reduction assays (Fig 5A). To determine the mutations that conferred the 
escape phenotype, RNA sequences obtained from plaque-purified escape variants were 
compared to wild type WNV sequence derived from virus passaged in parallel in the 
absence of antibody selection. All (5 of 5) sequences from CR4348 escape variants 
contained the same single nucleotide change encoding a T208I mutation in the E protein; 
in addition, two of the five sequences also had an independent H246Y mutation in the E 
protein. In contrast, all (15 of 15) CR4354 escape variants contained a single nucleotide 
mutation, encoding a K136E mutation in the E protein; no other nucleotide changes were 
observed in any of the CR4354 variants.  
To establish that these amino acid substitutions conferred the neutralization 
escape phenotypes observed, we utilized two reverse-genetic systems. First, RVP with 
single amino acid mutations were generated and analyzed for MAb neutralization. 
Whereas Hu-E16 neutralized all mutant and WT RVP equivalently, the T208I and K136E 
RVPs were not efficiently neutralized by CR4348 and CR4354, respectively, even at 
concentrations of 15 μg/ml of MAb (Fig 5B). H246Y RVP were neutralized by CR4348 
but only at the highest doses of antibody tested; the concentration at which 50% 
inhibition (EC50) occurred was increased by > 31-fold (P < 0.02) compared to the wild 
type RVP (see Fig 1B).  
As an independent confirmation, we introduced these substitutions into a wild 
type infectious New York 1999 WNV cDNA clone (NY99ic) (5) to generate mutant 
viruses. Analogous results were obtained with all genetically engineered mutant WNV 
and MAbs using a plaque reduction assay on BHK21-15 cells (Fig 5C). Thus, 
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experiments with the RVP and infectious cDNA clone confirmed the sequencing results, 
and suggest that CR4348 and CR4354 likely bind distinct epitopes on WNV E protein. 
To directly determine the contributions of these amino acids to MAb binding, we used 
the mutated NY99ic WNV in a capture ELISA (Fig 5D). As expected, Hu-E16 
recognized all three variant viruses. CR4354 failed to bind to WNV with a K136E 
mutation but did recognize the other viruses, establishing that a change in K136 confers a 
loss-of-binding phenotype. In contrast, no decrease in CR4348 binding was observed for 
the single T208I or H246Y variants or a double T208I/H246Y variant (data not shown). 
Thus, these two individual mutations, which strongly impact CR4348 neutralization, do 
not alter MAb binding in the capture ELISA. 
 To gain a better understanding of why CR4348 and CR4354 recognized intact 
virions or subviral particles but not recombinant E proteins, we mapped the residues that 
conferred escape from MAb neutralization onto the existing WNV E protein crystal 
structures (30, 58). K136, T208, and H246 are all solvent-accessible residues (Fig 6A). 
K136 is located at the end of DI adjacent to the hinge between DI and DII. This hinge 
rotates ~20-30º during structural rearrangement of the E protein associated with low pH-
induced viral fusion in late endosomes (7, 49). The flexibility of the DI-DII hinge may be 
less dynamic on an icosahedral virion or SVP compared to soluble recombinant protein, 
possibly explaining the differential reactivity of the CR4354 epitope. In contrast, the 
conformationally sensitive nature of CR4348 binding may be due to preferential 
reactivity with WNV E protein dimers. T208 and H246 are present in DII and, although 
relatively distant (~43Å) within an individual E protein monomer, are separated by ~19Å 
across the dimer interface, which is within the spatial limits of an antibody footprint (Fig 
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6B). It is important to note that in contrast to TBEV and DENV E proteins, which readily 
form dimers in solution, soluble WNV E protein is largely monomeric (30, 58). 
Consistent with the mapping and binding data that suggests the two human MAbs 
recognize distinct epitopes, CR4348 efficiently neutralized the K136E WNV variant and 
CR4354 inhibited infection of the T208I and H246P variants (data not shown). 
Given this mapping data, we hypothesized that CR4348 might recognize 
oligomeric forms of E protein that are not prevalent in our purified recombinant 
preparation. As mentioned, ELISA plates coated with WNV E protein overnight at 4ºC 
showed no immunoreactivity with either CR4348 or CR4354 (Fig 2B). However, coating 
plates with E protein at 37ºC resulted in a modest, yet significant signal by CR4348, 
possibly due to oligomeric interactions between E proteins that occur more favorably at a 
higher temperature, prior to adsorption (Fig 2B). 
Phenotype of WNV variants in cell culture. Comparison of E protein amino acid 
sequence of WNV isolates that varied geographically and temporally showed that T208 
and H246 were completely conserved. K136 was completely conserved among lineage 1 
WNV isolates, but varied in the less virulent lineage 2 and 3 strains with alanine and 
serine substitutions, respectively (data not shown). To evaluate whether the mutations 
associated with neutralization escape of CR4348 and CR4354 were functionally 
important for virus replication and affected viral virulence, growth analyses in BHK21-15 
cells was performed. The plaque morphology of the three mutant viruses (K136E, T208I, 
and H246Y) in BHK21-15 cells was compared to that of the wild type WNV New York 
1999 strain. The wild type, K136E and T208I variants had similar large plaque 
morphology whereas the H246Y mutant had a small plaque phenotype (data not shown).  
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In vivo protection studies. Passive transfer of neutralizing MAbs against WNV 
confers protection against disease in mice (22, 59, 61, 69, 78) and hamsters (53, 54). To 
evaluate the potency of the human MAbs, protection studies were performed in wild type 
C57BL/6 mice after infection with WNV-NY99ic. Analogous to results with Hu-E16 
(59), prophylaxis with low (1.4 and 0.4 µg, respectively) doses of CR4348 and CR4354, 
completely protected mice against lethal WNV encephalitis (Table 1). No protective 
effect was observed in these or other published studies (17, 59, 78) with isotype control 
antibodies. 
 To characterize in greater detail the protective activity of the more potent of the 
two neutralizing MAbs, CR4354, infection studies with wild type and K136E escape 
variant WNV were repeated in highly susceptible three to four week-old NIH Swiss 
Webster mice (Table 2); this strain was selected because WNV morbidity and mortality 
shows a linear virus dose dependence (4). Consistent with the cell culture plaque 
morphology data, the lethality of wild type and K136E WNV-NY99ic was not different, 
with LD50 values of 0.28 and 0.24 PFU, respectively (P > 0.8). Sequencing of viral RNA 
from brains of mice infected with wild type or K136E variant WNV-NY99ic revealed no 
amino acid changes: WNV in the brain after infection with wild type and mutant viruses 
contained K and E residues at position 136, respectively (data not shown). To confirm the 
neutralization escape phenotype, mice were pre-treated with 50 μg (~100 times the 
minimum protective dose in C57BL/6 mice) of CR4354 MAb one day prior to infection 
with ~3 x 101 PFU of wild type or K136E variant WNV-NY99ic. CR4354 protected 94% 
(15 of 16) of mice from WNV-NY99ic challenge, whereas only 19% (3 of 16) of mice 
challenged with K136E-NY99ic survived despite CR4354 prophylaxis. In contrast, Hu-
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E16 protected nearly all mice after infection with either wild type or K136E-NY99ic. 
Collectively, these data confirm the highly protective activity of CR4354 in vivo and the 
CR4354 escape phenotype of the K136E mutation. 
 53 
DISCUSSION 
 Previous studies suggested that antibodies that map to the DIII-lr epitope do not 
account for the majority of neutralizing activity in serum from human patients or horses 
(60, 70). In this study, we characterized the functional properties of two neutralizing 
human MAbs, CR4348 and CR4354 that recognize distinct epitopes. Both MAbs inhibit 
WNV infection in vitro and in vivo but did not recognize closely or distantly related 
flaviviruses, including SLEV or DENV (M. Throsby, M. Vogt and M. Diamond, 
unpublished results). Biochemical studies demonstrate that these MAbs have similar but 
not identical profiles: they bind to conformationally sensitive epitopes on E proteins 
displayed on virions or SVP in a pH-sensitive manner but recognize recombinant E 
protein in solution or displayed on the surface of yeast poorly, if at all. Functional 
experiments suggest that both human MAbs neutralize infection primarily at a post-
attachment stage in the viral lifecycle, specifically through inhibition of viral fusion with 
the endosomal membrane. 
 The CR4354 recognition site was established by neutralization escape and reverse 
genetic experiments and localized to the DI-DII hinge interface at residue K136. This 
hinge is highly flexible, as the angle between DI and DII on DENV E rotates 27º during 
the transition from the immature to mature state after furin-mediated cleavage of prM 
(87). The hinge then rotates back 30º during the pre- to post-fusion domain 
rearrangement (7, 49). Two X-ray crystal structures of similarly prepared WNV E protein 
also have distinct DI-DII hinge angles, differing by 5º (30, 58). This inherent flexibility 
of the DI-DII hinge could explain the lack of CR4354 binding to soluble and yeast 
surface displayed E, as these recombinant E proteins may not display the native hinge 
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that is found on virions or SVP. Indeed, exposure of SVP to acidic conditions that alter 
the DI-DII hinge angle significantly reduced binding of CR4354.  
Although the characteristics of CR4354 appear relatively unique among anti-
WNV MAbs, several other anti-flavivirus neutralizing MAbs have been described that 
localize to this region (Table 3). The anti-WNV MAb that maps closest to this region is 
the mouse MAb E113, which binds a determinant along the DI-DII hinge interface at 
residues E49 and K208 (see Fig 6C). E113 is protective in vitro (EC50 ~0.25 µg/ml) and 
in vivo, but unlike CR4354, E113 binds recombinant and yeast-displayed E proteins 
efficiently (61). The importance of this epitope for antibody neutralization is reflected by 
the characterization of several DI-DII inhibitory anti-flavivirus MAbs. Notably, MAbs 
(503, NARMA3, and B2) that recognize the DI-DII hinge are strongly inhibitory against 
the closely related JEV, which is a member of the same serogroup as WNV (21, 27, 35, 
52). 
 Neutralization escape experiments suggested T208 and H246 as recognition sites 
near the DII dimer interface for the CR4348 MAb. The importance of these residues for 
neutralization was confirmed using reverse genetic approaches by introducing these 
mutations into WNV RVP and the infectious cDNA clone. Although mutation of these 
two residues abolished neutralization they did not prevent CR4348 MAb binding in 
capture ELISA experiments, suggesting that other amino acids that were not revealed in 
our selection experiments contribute to the epitope. While T208 and H246 lie spatially far 
apart (~43Å) within the E monomer, likely beyond the footprint of the antibody paratope, 
they reside significantly closer (~19Å) across the dimer interface. Thus, CR4348 may 
recognize an epitope that is sensitive to the oligomeric state of the E protein. Consistent 
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with this, CR4348 does not stably bind WNV E on yeast or in the solid-phase when 
adsorbed at low temperature (4ºC). However, when WNV E was adsorbed to microtiter 
plates at 37ºC we reproducibly observed modest levels of binding. Furthermore, CR4348 
binds poorly to SVP that have been exposed to mildly acidic solutions; a decrease in pH 
induces a structural rearrangement in flavivirus E proteins, resulting in dimer dissociation 
and trimer formation (7, 49).  
The CR4348 MAb epitope is structurally and functionally unique among 
characterized anti-WNV MAbs. Although CR4348 recognizes residues at the DII dimer 
interface that are proximal to the E100 mouse anti-WNV E MAb (61), the two differ in 
several respects: E100 maps more distal from DI at residue H263, only modestly 
neutralizes WNV in cell culture (EC50 ~ 10 µg/ml), recognizes both soluble and yeast 
forms of E, and shows quite limited protective efficacy against lethal WNV infection in 
mice. However, a DII-dimer interface MAb with more similar properties has been 
described for the distantly related flavivirus, TBEV (Table 4). The A5 MAb (26) maps to 
residue E207 along the dimer interface (45), is strongly neutralizing in culture (26), and 
partially blocks TBEV fusion in the pyrene excimer liposome fusion assay (74). 
Moreover, binding of at least some cross-reactive neutralizing flavivirus MAbs (e.g., 4G2 
and 6B6C-1) that map to the fusion peptide in DII are also affected by mutation of 
residues (E231) along a dimer interface (10). One speculation as to why so few MAbs 
with these functional properties have been described is that they may not be identified 
with screens or immunization protocols using recombinant E proteins.  
 One limitation to mapping analyses by neutralization escape, which may be 
important for MAbs that show loss of function with mutations in a flexible hinge, is the 
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inability to exclude a distal binding site that is modulated allosterically by the hinge. A 
lack of binding to yeast or soluble E could reflect that these recombinant forms of E are 
truncated at amino acid 415 and lack the C-terminal stem-anchor and transmembrane 
regions. The lack of identification of an escape mutant in the highly conserved C-terminal 
regions could be due to poor viability of these variants. Unfortunately, because these 
MAbs bind poorly to recombinant E proteins, co-crystallography (44, 57), nuclear 
magnetic resonance (82), or saturation mutagenesis (23, 24, 46) approaches to identify 
the structural epitope are not possible. Instead, cryo-electron microscopy studies with 
Fab-virion complexes (31, 44) are planned to confirm the location of the epitope on the 
virion. Such experiments will be especially important for mAbs like CR4348, which 
shows a loss of neutralization but not binding with mutations at the DII dimer interface. 
 We previously described E16, a strongly neutralizing WNV-specific mouse MAb 
that maps to DIII-lr of the E protein (59) and inhibits infection by blocking viral 
membrane fusion in endosomes (B. Thompson, B. Moesker, J. Wilschut, J. Smit, M. 
Diamond, and D. Fremont, submitted for publication). Although CR4348 and CR4354 
also strongly neutralize infection and affect a post-attachment step in the viral life cycle, 
they likely inhibit WNV by a mechanism distinct from that of E16. CR4354 appeared to 
inhibit infection almost equivalently when it was added before or after attachment. In 
contrast, CR4348 and E16 showed somewhat enhanced neutralizing activity when added 
prior to attachment. Moreover, in the liposomal model system, E16 completely blocked 
fusion at different pH values ranging from 6.3 to 5.0, consistent with ELISA and surface 
plasmon resonance data showing pH-independent binding of E16 to SVP (B. Thompson 
et al, submitted). In contrast, CR4354 and CR4348 do not completely block low-pH-
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induced fusion of the virus with liposomes, with some residual fusion activity observed, 
respectively. This residual fusogenic activity in the setting of saturating concentrations of 
CR4354 and CR4348 may be due to heterogeneity among the WNV virions. Indeed, we 
also observed a small resistant fraction of virions in the classical PRNT50 analyses under 
conditions of antibody saturation, with ~10% and 20% of the virus remaining infectious 
in the presence of high concentrations of CR4354 and CR4348, respectively (Fig 1A). At 
present the molecular basis of the differences in residual infectivity or fusogenic activity 
of the two experimental systems under conditions of CR4354 and CR4348 excess 
remains uncertain. The residual non-neutralized fractions, however, are not likely related 
to the maturation stage of the virus (56), since mature and partially immature WNV RVP 
are neutralized equivalently by these MAbs. More detailed analysis of antibody-virion 
structures and the precise pH dependency of the inhibition are planned to further define 
the mechanisms of neutralization.  
 For WNV and other flaviviruses, passive immunotherapy has been shown to 
protect small animals against lethal infection even when administered several days after 
infection (22, 59, 68). As recent studies suggest that resistance to monotherapy with the 
E16 MAb can occur in vivo (84), the use of combinations of neutralizing MAbs that 
recognize distinct epitopes may be advantageous as has been demonstrated for a 
therapeutic antibody cocktail against the rabies virus (2). The characterization of potently 
neutralizing MAbs like CR4348 and CR4354 that map to distinct regions and inhibit by 
different mechanisms suggests that this may be feasible. 
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TABLE 1. Effect of MAb pretreatment on survival of C57BL/6 mice 
MAb Dose (μg) # of survivors/  
total # of mice 
% Survival P valuea 
PBS  4/20 20  
CR4348 14 4/4 100 ≤0.01 
CR4348 4.2 5/5 100 ≤0.01 
CR4348 1.4 5/5 100 ≤0.01 
CR4348 0.42 3/5 60 0.13 
CR4348 0.14 3/5 60 0.10 
CR4348 0.042 2/5 40 0.31 
CR4348 0.014 1/5 20 0.70 
CR4354 14 5/5 100 ≤0.01 
CR4354 4.2 5/5 100 ≤0.01 
CR4354 1.4 5/5 100 ≤0.01 
CR4354 0.42 5/5 100 ≤0.01 
CR4354 0.14 4/5 80 0.018 
CR4354 0.042 2/5 40 0.21 
CR4354 0.014 1/5 20 0.57 
 
a P values were determined using the log rank test and are compared to the PBS controls. 
C57BL/6 mice were pre-treated with the indicated dose of human MAb at day -1 by 
intraperitoneal injection. On day 0, mice were infected with WNV by subcutaneous route 
and monitored for survival. 
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TABLE 2. Effect of K136E substitution on MAb protection of NIH Swiss mice 
MAb NY99ic WNV # of survivors/  
total # of mice 
% Survival P valuea  
 
PBS wild type 4/16 25  
Hu-E16 wild type 16/16 100 <0.0001 
CR4354 wild type 15/16 94 <0.0001 
PBS K136E 1/16 6  
Hu-E16 K136E 15/16 94 <0.0001 
CR4354 K136E 3/16 19 0.37 
 
a P values were determined using the log rank test and compared to the PBS controls for 
each virus. 
NIH Swiss mice were pre-treated with 50 µg of human MAb (Hu-E16 or CR4354) at day 
-1. On day 0, mice were infected with 3 x 101 PFU/mouse of WT-NY99ic or K136E-
NY99ic virus and monitored for survival. 
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TABLE 3. Flavivirus MAbs that localize to the DI-DII Hinge Interface 
Name of 
MAb 
Virus Epitope Immunogen Source In 
vitro 
Neut. 
In 
vivo 
Neut. 
Ref. 
CR4354 WNV K136 Natural 
infection 
Human ++ ++ (78) and 
current 
paper 
 
E113 WNV E49, 
K280 
Infectious 
virus + 
recombinant 
E protein 
 
Mouse + + (61) 
503 JEV S275, 
K136, 
I126 
 
Infectious 
virus 
Mouse ++ ++ (34, 35, 
52) 
NARMA3 JEV Q52 Infectious 
virus 
 
Mouse ++ ND (27, 37) 
B2 JEV I126 Vaccine + 
infectious 
virus 
 
Chimpanzee ++ ++ (21) 
4B6C-2 MVEV A126, 
R128, 
F274, 
S276, 
S277 
Purified  
virus 
Mouse ++ ++ (28, 47) 
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++: greater than 90% inhibition via any in vitro assay, or capable of 90% protection in 
any lethal in vivo model 
+: any significant in vitro neutralization or in vivo protective capacity 
-: no significant in vitro neutralization or in vivo protective capacity 
ND: not determined 
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TABLE 4. Flavivirus MAbs that localize to the DII Dimer Interface 
Name of 
MAb 
Virus Epitope  Immunogen Source In vitro 
Neut. 
In vivo 
Neut. 
Ref. 
CR4348 WNV T208, 
H246 
Natural 
infection 
Human ++ ++ (78) 
and 
current 
paper 
 
E100 WNV H263 Infectious 
virus + 
purified E 
 
Mouse + + (61) 
A5 TBEV E207 Solubilized 
virus 
Mouse + ND (26, 45) 
 
++: greater than 90% inhibition via any in vitro assay, or capable of 90% protection in 
any lethal in vivo model 
+: any significant in vitro neutralization or in vivo protective capacity 
-: no significant in vitro neutralization or in vivo protective capacity 
ND: not determined 
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FIGURE LEGENDS 
 Figure 1. Neutralization and enhancement of human MAbs. A. PRNT50 assay. 
Hu-E16, CR4348, CR4354, and an isotype control MAb (DENV1-E50) were tested for 
neutralization activity by standard PRNT assay on BHK21-15 cells. Data shown are 
combined results of two independent experiments in triplicate. The data is normalized to 
data from from six control wells in each experiment with no MAb. B-C. RVP 
neutralization assay. Hu-E16, CR4348 and CR4354 were incubated with RVP prior to 
infection of Raji-DCSIGNR cells. RVP were prepared (B) normally or with the (C) 
T332K mutation in the E protein, which abrogates neutralization by virtually all all DIII-
lr MAbs. Data shown are representative of three independent experiments in duplicate. 
Error bars represent standard deviation and lines represent curve fits generated by 
nonlinear regression analysis. D. Hu-E16, CR4348, and CR4354 were tested for their 
ability to enhance WNV RVP infection of human CD32 (Fc-γRIIA) expressing K562 
cells. Data shown are representative of at least two experiments performed in triplicate.  
Error bars represent standard deviation. 
Figure 2. Binding of human MAbs to recombinant protein, SVP, and virions. 
A. Yeast display assay. WNV E protein ectodomain (amino acids 1-415, left) or DIII 
alone (amino acids 296-415, right) was expressed on the surface of yeast, stained with 
CR4348 (dotted), CR4354 (dashed), Hu-E16 (solid), or irrelevant human IgG1 (filled) 
MAbs, and detected by flow cytometry. One representative experiment of three is shown. 
B. ELISA. The ectodomain (amino acids 1-415) of E protein was adsorbed to microtiter 
plates for one hour at 37ºC or overnight at 4ºC. After blocking, wells were incubated with 
the indicated MAbs and ELISA was performed as detailed in the Methods. Data shown 
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are representative of three experiments performed in triplicate with error bars 
representing standard deviation. C. Western blot. Recombinant E protein ectodomain 
(~39 kDa), SVP (glycosylated full length E protein, ~44 kDa), or WNV virus 
(unglycosylated full length E protein, ~43 kDa) were assessed for binding by indicated 
human MAbs to E or prM (~15 kDa) proteins. Samples were prepared in SDS sample 
buffer with or without heating to 95ºC and with or without 5% (v/v) β-mercaptoethanol 
(β-ME). D. A capture ELISA was used to detect binding of MAbs to WNV SVP (left) 
and virions (right). Microtiter plates were coated with murine E16, incubated with SVP 
or virus, and detected with the indicated human IgG1 MAbs. Dashed lines indicate the 
background of the assay with an isotype control MAb. 
Figure 3. Effect of virus maturation state on neutralization by CR4348 and 
CR4354. CR4348 (left panel) and CR4354 (right panel) were incubated with MAbs prior 
to infection of Raji-DCSIGNR cells. RVP were prepared normally (mixture of mature, 
immature, and partially mature), in the presence of NH4Cl (immature), or in cells over-
expressing the furin protease (mature) to create virions of different maturation states. 
These were incubated with MAbs prior to infection of Raji-DCSIGNR cells. Data shown 
are combined results of three independent experiments in duplicate. 
Figure 4. Mechanism of WNV neutralization by CR4348 and CR4354. A. Pre- 
and post-attachment inhibition assays. To determine whether the MAbs neutralize WNV 
infection after cellular attachment, Vero cells were pre-chilled to 4 ºC and 102 PFU of 
WNV was added to each well for one hour at 4 ºC. After extensive washing at 4oC, the 
MAbs were added for one hour at 4ºC, and then the PRNT protocol was completed 
(dashed lines, Post). In comparison, a standard pre-incubation PRNT with all steps 
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performed at 4ºC is shown for reference. In this case virus and MAb are incubated 
together for one hour at 4oC, prior to addition to cells (solid lines, Pre). Data shown are 
representative of three experiments performed in duplicate with error bars representing 
standard deviation. B. pH sensitivity of MAb binding to SVP. The capture ELISA 
protocol was modified such that the pH was changed (6.0 or 7.4) for 30 minutes 
immediately before captured SVP were detected by indicated human IgG1 MAbs. One 
representative experiment of three performed in triplicate is shown, with error bars 
representing standard deviation. Dashed lines indicate the background of the assay with 
an isotype control MAb. C-D. Fusion of pyrene-labeled WNV with liposomes. C. 
Pyrene-labeled WNV was incubated with or without 50 nM of the indicated MAbs for 
one hour at room temperature prior to mixing with liposomes and acidification at pH 6.3. 
Fusion was measured on-line, as described in Materials and Methods. Representative 
fusion data of at least three independent experiments is shown. Curve a, no antibody; b, 
50 nM isotype-matched control; c, 50 nM CR4348; d, 50 nM CR4354. D. Extent of 
WNV fusion at increasing concentrations of antibody. The extent of fusion was 
determined at 60 seconds upon acidification and is shown as a percentage of the control 
(no antibody, pH 6.3). White bars, isotype-matched control MAb; dark gray, CR4348; 
light gray, CR4354. Representative fusion data of at least three independent experiments 
is shown. 
Figure 5. Characterization of neutralization escape mutants. A. PRNT assay 
performed in duplicate with virus after three passages under selection of either CR4348 
(left) or CR4354 (right) on Vero cells. Reduced neutralization capacity was observed 
compared to Hu-E16. B-C. Confirmation of resistant phenotype with reverse genetic 
 66 
RVP or infectious cDNA clone assays. Mutated (B) RVP and (C) infectious WNV were 
used to confirm that single amino acid substitutions of T208I (left), H246Y (middle), and 
K136E (right) in the E protein could reduce or eliminate neutralization by selecting MAb. 
In each series of experiments the reduced neutralizing capacity of the indicated human 
MAb is compared to Hu-E16, which maps to a distinct epitope on the DIII-lr. The data 
are combined data from two or three separate experiments performed in duplicate or 
triplicate. Error bars indicate standard deviation. Lines represent curve fits generated by 
non-linear regression analysis. D. A capture ELISA was used to detect binding of MAbs 
to mutated (K136E, T208I, and H246Y) WNV virions. Microtiter plates were coated with 
murine DIII-lr MAb, incubated with mutated virus, and detected with the indicated 
human IgG1 MAbs. Dashed lines indicate the background of the assay with an isotype 
control human MAb. The data are representative of three separate experiments performed 
in triplicate. Error bars indicate standard deviation. 
Figure 6. Structural mapping of MAb epitopes. A. WNV E protein dimer with 
K136 (CR4354) colored in blue and T208 and H246 (CR4348) colored in magenta. B. 
Close-up view of the WNV E DII dimer interface with the CR4348 epitope highlighted in 
magenta. C. Surface display model of WNV E DI-DII hinge region with epitope 
recognition sites of CR4354 and the corresponding WNV residues of other anti-flavivirus 
MAbs (E113, 503, NARMA3, B2, and 4B6C-2) listed in Table 4. Note that residue 136 is 
labeled CR4354 but also is part of the 503 epitope and residue 126 is labeled B2 but also 
is part of the 503 and 4B6C-2 epitopes. 
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INTRODUCTION 
West Nile virus (WNV) is a zoonotic mosquito-transmitted flavivirus that can 
infect and cause disease in humans and many other vertebrate animals. The flavivirus 
genus also contains other human pathogens of global relevance, including dengue 
(DENV), yellow fever, Japanese encephalitis, and tick borne encephalitis viruses. Most 
human WNV infections are asymptomatic, but about 20% of infected individuals 
experience a mild fever, and less than one percent develop severe neuroinvasive disease 
(67). Risk factors for symptomatic disease include an age of greater than 55 years, a 
compromised immune status, genetic variation in the OAS1 gene, and a CC5Δ32 
genotype (17, 26, 40, 41). Although WNV first appeared in the Western hemisphere in 
1999 in New York and spread rapidly through North America, surprisingly few human 
clinical infections have been reported in Central and South America despite the migration 
of avian hosts and appropriate vectors for transmission (35, 56). 
WNV infection requires attachment to cell surface receptors, which remain poorly 
defined, endocytosis, and acid-catalyzed fusion of the virus within the late endosome. 
After translation of input strand RNA and viral replication, progeny virion assembly 
occurs within the endoplasmic reticulum (ER), with the capsid protein and genomic RNA 
associating with pre-membrane (prM) and envelope (E) proteins (42). Virus particles bud 
into the lumen of ER as immature virions in which E and prM proteins interact to form 
60 heterotrimeric spikes with icosahedral symmetry (84). Transit of the immature virion 
through the mildly acidic compartments of the trans-Golgi network (TGN) triggers an 
extensive rearrangement on the virion surface. This low pH induced transition causes the 
E proteins on immature virions to lie flat as antiparallel dimers on the surface of the 
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virion (36), which in turn increases the susceptibility of prM to cleavage by a furin-like 
serine protease in the TGN (39, 82). Release of prM occurs in the neutral pH of the 
extracellular space (82). Mature flavivirus virions are relatively smooth particles that 
display 90 E protein dimers arranged in a herringbone pattern. While cleavage of prM is a 
required step in the viral lifecycle, it can be an inefficient process. Moreover, partially 
mature flavivirus virions containing some uncleaved prM also retain infectivity (29, 33, 
51). 
Studies in mice and other animals have established that humoral immunity is an 
essential component for protection against lethal WNV infection (57). B cells and 
secreted antibody were necessary for survival of mice after WNV inoculation (18, 19), 
and passive transfer of WNV-immune serum protected naive recipients from WNV 
challenge (22, 74). Moreover, pre-exposure prophylaxis and post-exposure therapy with 
WNV-specific monoclonal (MAb) or polyclonal antibodies conferred protection in both 
mice and hamsters (4, 6, 22, 48, 53, 71, 74, 75). The E protein of WNV is the principal 
target of neutralizing antibodies. Antibody neutralization occurs by blocking attachment 
to host cells, penetration of virions into cells, and the low pH-dependent fusion of the 
viral and host cell membranes (58). X-ray crystallographic analysis of several flavivirus 
E proteins has revealed a canonical structure with three domains (domain I (DI), domain 
II (DII) and domain III (DIII)). The generation and characterization of large panels of 
mouse and human MAbs against epitopes spanning the WNV E protein has enhanced our 
understanding of the antibody response to WNV. Although mouse MAbs that bind to all 
three domains of WNV E protein have been described, the most potently inhibitory 
MAbs recognize the lateral ridge epitope on DIII (DIII-LR) (2, 53, 64). In comparison, 
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the human anti-E repertoire appears more focused on a poorly neutralizing epitope on the 
fusion loop of DII (DII-FL) (54, 75). 
In this study, we examined the contribution of poorly neutralizing antibodies to 
protection against WNV infection. In particular, a fusion-loop specific MAb (E28), which 
had little detectable inhibitory activity in cell culture, protected mice against lethal WNV 
infection. Protection required antibody effector function, as survival benefit was lost in 
mice lacking activating Fc-gamma receptors (FcγR) and the complement opsonin C1q or 
when an aglycosyl E28 variant that cannot engage FcγR and C1q was administered to 
wild type mice. In subsequent mechanistic studies, we show that E28 treatment decreased 
viral load in the serum early in the course of infection, an effect that required cells with 
phagocytic activity. Finally, we demonstrate that human and hamster polyclonal antibody 
responses after DENV infection that cross-react with WNV are generally poorly 
neutralizing and skewed to the DII-FL epitope, and that passive transfer of IgG purified 
from DENV-immune hamsters also protects mice from lethal WNV infection. Our study 
establishes the functional significance of immunodominant poorly neutralizing antibodies 
in the polyclonal human anti-flavivirus response and highlights the limitations of current 
neutralization assays, which cannot account for the protective effects conferred by these 
antibodies in vivo.  
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MATERIALS AND METHODS 
Antibodies. All MAb and polyclonal antibodies used in this study were purified 
by protein A or protein G affinity chromatography. Anti-WNV mouse MAbs E24, E28, 
E34, and E53 have been described previously (53, 55). Mouse isotype controls 
recognized dengue virus envelope (E) (DENV-2 E70, IgG1) (70) and precursor-
membrane (prM) (2H2, IgG2a) (25) glycoproteins and do not cross-react to WNV. 
Chimeric versions of MAb E28 (Ch-E28 and Ch-E28 N297Q) were generated by cloning 
the variable (VH and VL) regions of murine MAb E28 upstream of human IgG1 constant 
regions and performing site-directed mutagenesis as described previously for chimeric 
versions of MAb E16 (53). The negative control chimeric mouse-human IgG1 MAb (Ch-
4420) was specific for fluorescein isothiocyanate (FITC) (3). PK136, a hybridoma 
producing mouse anti-mouse-NK1.1 MAb (IgG2a), was the gift of W. Yokoyama (St 
Louis, MO). RB6.8C5, a hybridoma producing rat anti-mouse-Gr-1 MAb (IgG2b), was 
the gift of E. Unanue (St Louis, MO). A negative control rat IgG was purchased (Jackson 
ImmunoResearch). Hamster IgG was isolated from the serum of naïve or DENV-2 
infected golden Syrian hamsters (Harlan). Human serum was the gift of R. Akkina and S. 
Halstead (Pediatric Dengue Vaccine Initiative) and A. de Silva (Chapel Hill, NC). Serum 
was collected from individuals who had experienced multiple infections in the past with 
more than one serotype of DENV as judged by clinical history and PRNT titer analysis. 
The sera had the following reciprocal PRNT50 values against DENV-1, DENV-2, DENV-
3, and DENV-4, respectively: #1 (640, 611, 213, and 319); #2 (371, 320, 288, and 
>1,280); #3 (>1,280, 300, 99, and 266); #4 (>1,280, >1,280, >1,280, and 285); #5 (589, 
>1,280; 717, and 82); and #6 (>1,280, >1,280, >1,280, and 187).  
   92
The following antibodies against mouse antigens were conjugated to fluorescent 
markers and used in flow cytometry experiments: anti-CD11b-Alexa Fluor 647 (AF647) 
(M1/70), anti-CD45-peridinin chlorophyll protein (PerCP) (30-F11), anti-Ly6C-
phycoerythrin (PE) (AL-21), and anti-Ly6G-PerCP-Cy5.5 (1A8). The conjugated 
antibodies listed above were purchased from BD Biosciences. Anti-CD3ε-AF647 (145-
2C11) was purchased from BioLegend, anti-NKp46-PE (29A1.4) was purchased from 
eBioscience, and anti-human IgG-AF647 was purchased from Invitrogen. 
Virus stocks. The WNV strain (3000.0259) was isolated in New York in 2000 and 
described previously (20). The virus was passaged twice in C6/36 Aedes albopictus cells 
to generate a stock virus that was used in all in vivo experiments. In vitro studies utilized 
a virus stock that was passaged one additional time in C6/36 or Vero cells. An in vivo 
derived stock of WNV was generated from plasma three days after infection of AG129 
mice as described below. WNV subviral particles (SVP) were generated as described 
previously (80) by transiently transfecting a pcDNA3.1 plasmid encoding the prM and E 
proteins into 293T cells and harvesting cell culture supernatant after 48 hours. WNV 
reporter virus particles (RVP) that differ with respect to the extent of prM cleavage were 
generated as described previously (51). 
Mouse experiments. Mouse studies were approved and performed according to 
the guidelines of the Washington University School of Medicine Animal Safety 
Committee. All wild type C57BL/6J mice were purchased from a commercial source 
(Jackson Laboratories). Congenic C1q-/- mice were originally obtained from M. Botto and 
G. Stahl (Imperial College, London and Beth Israel Deaconess Medical Center, Boston, 
MA). Congenic FcγRI-/- mice were originally obtained from S. Verbeek (Leiden 
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University Medical Center, Leiden, The Netherlands). Congenic common gamma chain-
deficient (FcγR-/-), which lack FcγRI, FcγRIII, and FcγRIV, and FcγRIII-/- mice were 
purchased commercially (Taconic). The C1q-/- x FcγRI-/-, C1q-/- x FcγR-/- and C1q-/- x 
FcγRIII-/- mice were generated by crossing the individual knockout mice. All mice were 
bred and maintained in pathogen-free barrier facilities. Purified antibodies were 
administered to mice diluted in endotoxin-free PBS (HyClone Laboratories) by an 
intraperitoneal route. WNV was diluted in Hank’s balanced salt solution (Mediatech, 
Inc.) containing 1% heat-inactivated fetal bovine serum (FBS) (Omega Scientific) and 
administered by subcutaneous injection in the footpad after anesthetization with xylazine 
and ketamine. For NK cell depletion, mice were administered the PK136 anti-NK1.1 
antibody (100 µg) two days before and after infection with WNV. For neutrophil and 
inflammatory monocyte depletion, mice were given the RB6.8C5 anti-Gr-1 antibody (250 
µg) one day before infection with WNV. 
To isolate serum, blood was collected in Serum Gel Z tubes (Sarstedt), allowed to 
clot on ice for 30 minutes, centrifuged, and the liquid phase aliquoted and stored at -80ºC. 
Viral RNA was isolated from serum using the QIAamp Viral RNA Mini Kit (QIAGEN), 
stored at -80ºC, and quantified utilizing TaqMan quantitative reverse transcriptase qRT-
PCR on a 7500 Fast Real-Time PCR System (Applied Biosystems) as described 
previously (18). For plasma isolation, blood was collected into chilled 
ethylenediaminetetraacetic acid (EDTA) coated tubes (Becton Dickinson) on ice, 
centrifuged at 4°C, and the liquid phase aliquoted and stored at -80ºC. For tissue 
harvesting, mice were anesthetized with xylazine and ketamine and perfused extensively 
with PBS prior to organ dissection. Tissues were placed on dry ice, weighed, and stored 
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at -80ºC. Tissues were subsequently homogenized in PBS and virus was titrated by 
plaque assay on BHK21-15 cells. 
Flow cytometry. For preparation of splenocytes as single cell suspensions, spleens 
were manually homogenized on 40 µm cell strainers into RPMI medium (Sigma). For 
preparation of peripheral blood leukocytes (PBL), blood was collected into EDTA-coated 
tubes, and erythrocytes were lysed by diluting whole blood in ACK buffer (0.15 M 
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for five minutes. Splenocytes or PBL were 
washed thrice in PBS with 2% FBS prior to staining with cell type-specific conjugated 
MAbs for 30 minutes on ice. Cells were washed thrice and then analyzed on a 
FACSCalibur flow cytometer (BD Biosciences) using FlowJo software (Treestar). 
Liposomes. Clodronate liposomes were prepared according to published methods 
(60, 79). Briefly, 8 mg of cholesterol and 86 mg of phosphatidyl choline (Sigma-Aldrich) 
were dissolved in chloroform. Excess chloroform was removed under vacuum. Clodronic 
acid disodium salt (Cl2MDP, Sigma-Aldrich) was dissolved in de-ionized water and the 
pH adjusted to 7.3 with 5 N NaOH. The dry lipid pellet was resuspended in either 2.5 g 
of Cl2MDP in 10 ml of water for macrophage-depleting liposomes or PBS for control 
liposomes. Liposomes were washed with PBS by ultracentrifugation (Beckman L-80 
ultracentrifuge with 70.1 Ti rotor at 22,000 x g for 30 min) and resuspended in a final 
volume of 4 ml of PBS. To confirm that clodronate-containing lipsomes effectively 
depleted macrophages, C57BL/6 RAG1-/- mice were injected intravenously with 250 µL 
of liposome suspension and splenocytes were analyzed by flow cytometry 24 hours later 
for expression of CD11b and CD11c markers. For experiments in wild type mice, 
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liposomes were administered intravenously one day prior to and one day after WNV 
infection. 
Neutralization assays. (i) PRNT. Classical plaque reduction neutralization tests 
(PRNT) were performed as described previously on BHK21-15 cells after infection with 
50 to 125 PFU of WNV (80), depending on the assay. EC50 values were generated by 
nonlinear regression analysis (GraphPad Software). (ii) RVP. Neutralization assays with 
WNV reporter virus particles (RVP) expressing GFP were performed with Raji-
DCSIGN-R cells as described previously (59). (iii) Multi-step growth curve. WNV was 
mixed with individual MAbs (30 µg/ml) in Dulbecco’s Modified Eagle Medium 
(DMEM) with 10% FBS for one hour at 37ºC, then added to a monolayer of BHK21-15 
cells at a MOI of 0.001 and incubated for specified times at 37ºC. Supernatants were 
collected at the indicated times, aliquotted, stored at -80ºC, and quantified by plaque 
assay on BHK21-15 cells. (iv) Raji-DCSIGN-R cells and infectious virus. WNV was 
mixed with individual MAbs (30 µg/ml) in RPMI-1640 with 5% FBS for one hour at 
37ºC and added to Raji-DCSIGN-R cells (MOI of 0.001) and incubated for 28 hours at 
37ºC. Cells were fixed with 4% paraformadehyde, permeabilized with saponin (0.1% 
w/v), stained for WNV antigen (1o Ab: Ch-E16; 2o Ab: goat anti-human IgG-AF647) and 
processed on a FACSArray flow cytometer (BD Biosciences) using FlowJo software 
(Treestar). 
SVP and protein ELISA. Nunc MaxiSorp polystyrene 96-well plates were coated 
overnight at 4ºC with E24 MAb (10 μg/ml) in a pH 9.3 carbonate buffer. Plates were 
washed thrice in ELISA wash buffer (PBS with 0.02% Tween 20) and blocked for one 
hour at 37ºC with ELISA block buffer (PBS, 2% bovine serum albumin, and 0.02% 
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Tween 20). WNV SVP were captured for one hour at room temperature. Subsequently, 
plates were rinsed five times in wash buffer and then incubated with anti-WNV or 
flavivirus monoclonal or polyclonal antibodies (human or hamster) or controls (human 
IgG1 anti-FITC or naïve hamster antibodies) in duplicate for one hour at room 
temperature. Plates were washed five times and then incubated with biotinylated goat 
anti-human or hamster IgG (1:1000 dilution; Jackson ImmunoResearch) for one hour at 
room temperature in blocking buffer. After further rinsing, plates were incubated with 2 
μg/ml of horseradish peroxidase conjugated streptavidin (Vector Laboratories) for 30 
minutes at room temperature. Plates were washed six times and developed with 
tetramethylbenzidine (TMB) substrate (Dako). The reaction was stopped with 2N H2SO4 
and emission (450 nm) was read on a TriStar microplate reader (Berthold Technologies). 
For quantification of the epitope specificity of anti-WNV E hamster IgG and human 
serum, plates were coated with 10 µg/ml of recombinant WNV E proteins produced in E. 
coli (wild type, W101R mutant, or E-quadruple mutant (T76R, M77E, W101R, and 
L107R)) as described previously (54). The E-quadruple mutant was the gift of C. Nelson 
and D. Fremont (St. Louis, MO). Equivalent site density was confirmed by measuring 
reactivity with E24 or Ch-E16 MAb, both of which recognize a distinct epitope on DIII-
LR. Endpoint titers were defined as three standard deviations above the background 
optical density at 450 nm as determined by regression analysis using GraphPad Prism 
(GraphPad Software).  
Western blotting. Individual preparations of WNV (106 PFU) were inactivated in 
0.1% NP-40 detergent at 55ºC for 15 minutes. Subsequently, 4X lithium dodecyl sulfate 
sample buffer (Invitrogen) was added, and samples were heated to 95ºC for ten minutes, 
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centrifuged briefly, and loaded onto a Nu-PAGE 10% Bis-Tris gel (Invitrogen). After 
electrophoresis, the gel was rinsed in ddH2O and protein was transferred to a 
nitrocellulose membrane using the iBlot system (Invitrogen). Membranes were washed 
for ten minutes in wash buffer (PBS with 0.05% Tween 20), incubated overnight at 4ºC 
in blocking buffer (5% dry milk in wash buffer), and with human anti-E Ch-E16 MAb or 
polyclonal rabbit anti-M (Imgenex) at 1 µg/ml in blocking buffer for two hours. 
Following five rinses in wash buffer, membranes were incubated with horseradish-
peroxidase conjugated goat anti-human IgG (Sigma) or anti-rabbit IgG (Thermo 
Scientific) diluted 1:2000 in blocking buffer for one hour. After five additional rinses, the 
blots were developed with Amersham ECL reagent (GE Healthcare) and visualized after 
exposure to x-ray film.  
Statistical analysis. Survival studies were analyzed using the log rank test. 
Comparisons of viral titers utilized either the Mann-Whitney non-parametric t test or one-
way ANOVA as indicated. A paired student’s t test was used for comparisons of hamster 
IgG and human serum titers against different recombinant E proteins. Neutralization 
curves were compared using the F test. 
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RESULTS 
 Poorly neutralizing MAbs protect mice from WNV infection. While the plaque 
reduction neutralization test (PRNT) and analogous assays are viewed as a standard 
measure of inhibitory activity of antibodies against many viruses, an imperfect 
correlation has been observed for DENV between the degree of neutralization in vitro 
and protection in vivo (9). To explore this concept further, we assessed the protective 
activity in vivo of several previously characterized murine MAbs against the WNV E 
glycoprotein and their corresponding neutralizing capacity as judged by the PRNT assay 
on BHK21-15 cells. In the absence of passively transferred antibody, as seen previously 
(22), administration of 102 PFU of insect cell-derived WNV via a subcutaneous route to 4 
to 5 week-old wild type C57BL/6 mice resulted in a 14% survival rate (Table 1). While 
prophylaxis one day prior to infection with 40 µg of two strongly neutralizing domain III-
lateral ridge-specific (DIII-LR) MAbs (E24 (IgG2a) and E34 (IgG1), PRNT50: 4.0 and 80 
ng/ml, respectively) provided strong protection (≥ 90% survival, P < 0.0001), passive 
transfer of poorly- (E53 (IgG2a)) and non- (E28 (IgG1)) neutralizing domain II-fusion 
loop-specific (DII-FL) MAbs still provided significant protection (43%, P = 0.003 and 
60%, P < 0.0001 respectively), albeit it at lower levels (Table 1; Fig 1A). Thus, the 
capacity for anti-WNV MAbs to protect in vivo does not correlate perfectly with results 
from the PRNT assay in cell culture. 
 In vitro characterization of poorly neutralizing MAbs. The inability of the PRNT 
assay to predict MAb protection in vivo warranted further investigation. Previous studies 
established that the relative maturity of WNV virions as reflected by the degree of 
cleavage of prM protein affects the neutralizing activity of MAbs that recognize some 
(e.g., DII-FL) but not other (DIII-LR) epitopes (51). As seen previously (51), E53 
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neutralized infection in Raji-DCSIGN-R cells of mature WNV reporter virus particles 
(RVP) produced in a cell line over-expressing furin to a lesser extent than those generated 
in the parent cells, which produce a mixture of mature and partially immature virions. In 
comparison, E24 neutralized both types of RVP equivalently (data not shown). In 
contrast to the classical PRNT assay with BHK21-15 cells and similar to results with 
E53, E28 consistently showed a low but measurable neutralization (~30%) of mature 
RVP in Raji-DCSIGN-R cells (Fig 1B). The modest ability of E28 to neutralize WNV 
RVP was not a cell type-specific effect, as E28 (30 µg/ml) failed to neutralize infection 
of Raji-DC-SIGNR cells with C6/36-derived fully infectious WNV, and in fact enhanced 
infection compared to controls  (Fig 1C).  
 To assess whether the maturation state of WNV also affected neutralization in the 
PRNT assay, we propagated WNV in Vero cells, which produce virions that are more 
mature relative to those derived from C6/36 insect cells (Fig 1D and (24)). Similar to data 
with insect cell-propagated WNV, DIII-LR-specific MAbs E24 and E34 completely 
neutralized Vero cell-derived WNV with similar PRNT50 values, whereas E28 showed no 
appreciable inhibitory activity across a wide dose range (Fig 1E). Again, E53 showed 
partial neutralizing activity of Vero cell-derived WNV achieving ~50% overall 
inhibition, although its potency was shifted 500-fold (P < 0.0001) to a requirement for 
higher concentrations of MAb. Thus, E28 lacked neutralizing activity of insect or 
mammalian cell-generated WNV on BHK21-15 cells, whereas a decreased state of 
maturity of WNV RVP was associated with some inhibitory activity in Raji-DCSIGN-R 
cells.   
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 Since the source of WNV affected the level of neutralization observed in different 
cell types, we assessed the capacity of MAbs to inhibit WNV infection with virus 
produced in vivo. Because the recovery of infectious extracellular WNV from plasma of 
wild type mice is challenging due to limited viremia, we infected highly susceptible 
AG129 mice, which lack receptors required for type I and type II interferon signaling. 
Plasma-derived WNV was not neutralized by E28 at any concentration tested (Fig 1F), 
results that may be explained by the completely mature phenotype of WNV in plasma, as 
uncleaved prM was not observed by Western blot (Fig 1D). Of note, E24 was 600-fold 
less potent (P < 0.0001) at neutralizing infection of plasma-derived WNV (PRNT50 = 2.4 
µg/ml) than insect-derived WNV (PRNT50 = 4.0 ng/ml), which could be due to the 
enhanced E protein content of plasma-derived WNV that was observed at equivalent PFU 
compared to WNV preparations from C6/36 and Vero cells (Fig 1D) or to the existence 
of a neutralization escape variant. Finally, higher concentrations of E28 paradoxically 
augmented infection of plasma WNV preparations. This could be due to MAb-induced 
virus aggregation, as BHK21-15 cells lack expression of FcγR, precluding the possibility 
of “classical” antibody-dependent enhancement of infection (30). Collectively, these 
results suggest that the PRNT assay on BHK21-15 cells does not always predict the 
protective activity of WNV in mice even when accounting for different sources of virus, 
including those derived in vivo. 
 To further characterize the intrinsic neutralization capacity of anti-WNV MAbs 
on BHK21-15 cells, we performed multi-step growth curve analysis. While the addition 
of E24 (30 µg/ml) prior to infection resulted in complete neutralization, equivalent 
concentrations of E28 provided no reduction in viral titer compared to the isotype 
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antibody or medium controls (Fig 1G). Despite conferring protection in mice in passive 
transfer studies, and in contrast to E24, E28 had limited inhibitory activity in cell culture 
that was maturation state and cell-type-dependent. 
 E28 MAb prophylaxis reduces viral load in wild type mice. To gain further 
insight into how prophylaxis with the poorly neutralizing E28 MAb protects against 
WNV infection in vivo, passive transfer experiments were repeated, but mice were 
sacrificed and their organs collected for viral burden analysis at different time points. 
Mice receiving E28 MAb had lower levels of WNV in serum at days 1 and 2 post-
infection (~3.4-fold, P < 0.002 and ~6.5-fold, P < 0.0001, respectively) compared to the 
PBS-treated animals as measured by quantitative RT-PCR of viral RNA (Fig 2A). 
Correspondingly, mice treated with E28 MAb had decreased (~100-fold, P < 0.04) levels 
of infectious WNV in the brain at day 7 after infection (Fig 2B). Although differences of 
WNV in the brain did not attain statistical difference at day 5 (P > 0.2), nearly half of the 
E28 MAb-treated mice had levels at or below the limit of detection of the assay, whereas 
all PBS-treated mice had measurable WNV titers. Thus, treatment with E28 MAb altered 
the course of WNV infection at an early stage, which impacted dissemination and 
replication at later phases of pathogenesis.  
 C1q and activating Fc-gamma receptors are required for in vivo protection by 
E28 MAb. Since E28 MAb had little neutralizing activity in cell culture assays yet 
protected against WNV infection and pathogenesis, we hypothesized that Fc-mediated 
effector functions of the MAb contributed to the observed in vivo effects. To test this, 
congenic mice deficient in the complement component C1q were administered MAbs one 
day prior to WNV infection. Older 8 to 12 week-old mice were used for these studies as 
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these immunodeficient strains are inherently more susceptible to WNV pathogenesis 
compared to wild type mice (14, 43, 53) and older C57BL/6 mice (up through 24 weeks) 
are more resistant to infection (12, 22). In mice lacking C1q, which initiates the antibody-
dependent classical pathway of complement activation, 400 µg of E53 MAb prevented (P 
= 0.02) mortality caused by WNV infection (Table 2A). Whereas a lower dose (40 µg) of 
E28 MAb increased the survival time of C1q-/- mice by three days (P < 0.02), this dose of 
E53 and E28 failed to provide statistically significant protection against WNV mortality 
(Table 2A and Fig 3A). The partial, albeit limited protection by E28 in C1q-/- mice was 
somewhat surprising as this MAb is of the IgG1 isotype, which binds mouse C1q with 
low affinity (8). However, some mouse IgG1 MAbs bind complement better than others 
(23). Consistent with a functionally significant interaction, in vitro experiments showed 
that the addition of mouse C1q limited E28-mediated enhancement of infection in cells 
expressing FcγR (data not shown).  
 Mice lacking the common γ-chain of activating FcγR lack surface expression and 
signaling from FcγRI (CD64), FcγRIII (CD16), and FcγRIV (52). To assess the impact of 
FcγR-mediated effector functions on the protective capacity of poorly neutralizing MAbs, 
prophylaxis studies were repeated in mice lacking the common γ-chain (FcγR-/-). Passive 
transfer of 40 µg of E28 and 400 µg of E53 protected FcγR-/- mice against lethal WNV 
infection (Table 2B and Fig 3B). Because we hypothesized that complement and FcγR-
mediated effector functions might jointly contribute to the protective capacity of poorly 
neutralizing MAbs, we generated C1q-/-x FcγR-/- mice. Notably, 400 µg doses of E28 and 
E53 MAbs did not prevent lethality in C1q-/-x FcγR-/- mice, although robust protection 
was observed with strongly neutralizing DIII-LR MAbs (Table 2C and Fig 3C). A 
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requirement for FcγRIII for E28- and E53-mediated protection was inferred from passive 
transfer experiments with C1q-/-x FcγRIII-/- mice as statistically significant protection also 
was lost (Table 2D). Collectively, these results suggest that Fc-mediated effector 
functions (C1q and FcγR) are required for the protective activity of poorly neutralizing 
anti-WNV antibodies.  
To confirm independently that Fc effector functions of poorly neutralizing MAbs 
were required for protection in vivo, we engineered chimeric versions of E28 that retained 
or lost the ability to interact with C1q and FcγR. The variable (VH and VL) regions of 
mouse E28 were cloned upstream of the human IgG1 constant regions, and a chimeric 
mouse-human MAb (Ch-E28) was expressed as a wild type and aglycosyl variant; the 
latter contains a mutation (N297Q) in the heavy chain that eliminates binding to C1q and 
all FcγR (72). Wild type Ch-E28 and N297Q Ch-E28 bound to WNV virions equivalently 
in a capture ELISA (Fig 4A) yet still lacked neutralizing activity as judged by PRNT 
assay on BHK21-15 cells with C6/36-derived WNV (Fig 4B). While wild type Ch-E28 
provided significant protection against mortality (P = 0.03) in 4 to 5 week-old wild type 
mice infected with WNV, N297Q Ch-E28 failed to do so (Fig 4C). Accordingly, 
treatment with Ch-E28 but not Ch-E28 N297Q was associated with reduced WNV levels 
in the brain at day 7 after infection (Fig 4D). These experiments confirm that Fc effector 
functions are required for in vivo protection by the poorly neutralizing MAb E28. 
 B, T, and NK cells are not required for E28 MAb-mediated protection. We 
hypothesized that E28 MAb could promote viral clearance directly through enhanced 
complement and FcγR-dependent uptake, as described previously with MAbs against 
WNV NS1 (14, 15), or that E28-dependent immune complex formation and uptake could 
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promote antigen presentation and adaptive immune responses. To address the latter 
possibility, passive transfer studies were repeated in RAG1-/- mice, which lack B and T 
cells; as these mice are highly vulnerable to lethal WNV infection (22, 83), a lower 
infecting dose of virus (1 PFU) was used and protection was assessed by a virologic 
rather than survival endpoint. Notably, RAG1-/- mice receiving E28 MAb showed lower 
levels (≥ 5-fold, P < 0.008) of WNV in serum over time compared to the isotype control 
(Fig 5). While this experiment does not completely eliminate a possible role of B and T 
lymphocytes in contributing to E28-mediated protection in vivo, it establishes that these 
cells are not required for protection in vivo. 
 Our prophylaxis experiments with C1q-/- and C1q-/- x FcγRIII-/- mice suggested 
that some effector functions utilized by E28 for protection occur through FcγRIII-
dependent pathways. Given that natural killer (NK) cells express high levels of FcγRIII 
and use this receptor for antibody-dependent cellular cytotoxicity (ADCC) in vivo (62), 
we hypothesized that NK cells might be essential for E28-mediated protection. To assess 
this, 4 to 5 week-old wild type mice were administered 100 µg of a murine IgG2a control 
MAb or PK136, an anti-NK1.1 MAb that depletes NK cells (73). At days 2 and 4 after 
treatment, mice given PK136 showed significant depletion of NK cells as expected (Fig 
6A). However, depletion of NK cells had no impact on E28 MAb-mediated protection as 
judged by survival (Fig 6B) in mice treated with PK136 (100 µg) one day prior to WNV 
infection and again three days after infection. Thus, NK cells are not necessary for E28-
mediated protection from WNV. 
 Phagocytic cells contribute to E28 MAb-mediated protection. As B, T, and NK 
cells were not required for protection, we hypothesized that E28 might opsonize virus for 
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phagocytosis by cells expressing FcγR and complement receptors. To test their 
contribution to E28-mediated protection after WNV infection, we non-selectively 
depleted phagocytes using clodronate liposomes (77). To confirm depletion, splenocytes 
were analyzed for expression of the myeloid cell markers CD11b and CD45 one day after 
liposome injection. As expected, treatment with clodronate-containing liposomes 
depleted CD45intCD11bhi and CD45hiCD11bint cells (Fig 7A), which corresponds to 
myeloid cells with phagocytic capacity. To determine whether phagocytes were 
necessary for E28-mediated protection, 8 to 12 week-old wild type mice were 
administered liposomes containing clodronate or PBS and 500 µg of E28 or isotype 
control MAb one day prior to infection with 1 PFU of WNV, and then given a second 
dose of liposomes on day 1 post-infection. The experimental design was altered from the 
initial survival studies because wild type mice treated with clodronate liposomes are more 
vulnerable to WNV infection (5, 60). Clodronate liposome treatment resulted in a loss of 
protection by E28 MAb as judged by elevated levels of WNV in serum at days one and 
two post-infection compared to mice given liposomes containing PBS (Fig. 7B). Thus, 
phagocytes are required for the early reduction in viremia mediated by E28. 
 Neutrophils and inflammatory monocytes are innate immune cells that express 
FcγR and complement receptors and could contribute to E28 MAb-mediated clearance. 
To determine if these cells were necessary mice were administered RB6.8C5 (250 µg), a 
rat anti-mouse Gr-1 MAb that depletes cells expressing Ly6C and Ly6G (Fig 7C), 
including neutrophils, inflammatory monocytes, suppressor monocytes, and plasmacytoid 
dendritic cells (21). RB6.8C5 or control antibody was given one day prior to infection 
and E28 (500 µg) treatment. Notably, E28 MAb treatment decreased serum viremia on 
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day two post-infection regardless of whether mice had received RB6.8C5 or control 
antibody (Fig 7D), indicating that Gr-1 expressing cells were not required for E28-
mediated protective effects in vivo. Combined with the clodronate liposome data, these 
results suggest that phagocytic CD11b+ macrophages may be the primary cell type 
responsible for much of the protective activity of E28 in vivo. 
 Poorly neutralizing, E28-like polyclonal antibodies protect mice from WNV 
infection. While the WNV epidemic spread rapidly across North America, few human 
clinical infections have been reported in Central and South America despite the presence 
of the virus in avian and mosquito hosts (28, 56). Although this could reflect reporting 
bias, we hypothesized that prior widespread exposure to DENV and other endemic 
flaviviruses could result in production of polyclonal DII-FL-specific antibodies that failed 
to neutralize WNV infection by conventional PRNT analysis but still protected humans in 
vivo. Indeed, DII-FL antibodies are immunodominant in humans after infection with 
several flaviviruses (16, 54, 69, 75). To test whether polyclonal antibodies had E28-like 
epitope specificity and functional activity and would behave similarly against WNV in 
vivo, golden Syrian hamsters were inoculated with DENV type 2 (DENV-2) and 
polyclonal IgG was isolated by affinity chromatography from serum that was collected 
four weeks after infection. Hamsters were used rather than mice because the latter have 
their antibody response skewed toward the DIII-LR epitope (54). Notably, DENV-2 
immune hamster IgG bound more avidly to WNV virions than naïve IgG in a capture 
ELISA (Fig 8A). DENV-2 IgG failed to neutralize WNV infection by PRNT assay on 
BHK21-15 cells (Fig 8B, PRNT50 < 1/15 serum dilution), although some inhibition of 
Raji-DCSIGN-R cell infection was detected with partially mature but not mature WNV 
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RVP (Fig 8C). Thus, polyclonal DENV immune hamster IgG has similar in vitro 
neutralization characteristics as MAb E28. 
The vast majority of DII-FL-specific MAbs, including E28, lose binding to 
recombinant E protein that encodes a single W101R mutation (54). However, E53 retains 
binding to E-W101R but does not bind a recombinant E protein with three additional 
mutations within and proximal to the fusion loop (T76R, M77E, W101R, and L107R (E-
quadruple mutant)). Polyclonal DENV-2 immune hamster IgG that cross-reacted with 
WNV E protein was skewed toward the DII-FL epitope (W101R: 83% ± 13% binding, P 
< 0.005; quadruple mutant: 90% ± 7.7% binding, P < 0.002) as determined in direct 
binding assays to wild type and mutant recombinant E protein (Fig 8D). As most of the 
DENV-2 immune hamster cross-reactive IgG recognized the DII-FL epitope and did not 
neutralize WNV infection in BHK21-15 cells, we tested it for protective activity in vivo. 
Similar to results with E28 MAb, passive transfer of DENV-2 immune hamster IgG one 
day prior to WNV infection significantly (P = 0.03) protected 4 to 5 week-old mice 
compared to naïve IgG (Fig 8E). Thus, poorly neutralizing cross-reactive polyclonal 
antibodies derived from heterologous flavivirus infection can mitigate WNV infection in 
vivo. 
 The cross-reactive antibody repertoire of serum from DENV immune humans is 
skewed toward the DII-FL epitope. Having demonstrated that polyclonal anti-DENV-2 
hamster IgG was non-neutralizing yet protective against WNV infection in mice, we 
questioned whether similar trends would be observed with human serum from DENV-
immune individuals. Serum with cross-reactivity to WNV was obtained from patients 
with a history of infection of at least two serotypes of DENV (S. Halstead and A. de 
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Silva, personal communication). Analogous to that seen with hamster IgG, polyvalent 
DENV immune human serum that cross-reacts with WNV E protein was skewed toward 
the DII-FL epitope (Fig 9A). Although variability was observed in the loss of binding to 
E-W101R (51% ± 42% binding, P < 0.05), loss of binding to E-quadruple mutant was 
more consistent (82% ± 14% binding, P < 0.005). Only one of the six sera tested 
neutralized WNV infection by >50% (PRNT50 = 1/180 for sample #3). None of the 
remaining five human immune sera neutralized WNV by 50% at the lowest serum 
dilution tested (Fig 9B, PRNT50 < 1/20 serum dilution), establishing that humans infected 
with DENV produce DII-FL antibodies that cross-react to WNV yet poorly neutralize 
infection. However, given the limited available quantities of human sera, we could not 
directly test for protective capacity in passive transfer experiments in mice. 
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DISCUSSION 
A prior study suggested that DII-FL MAbs neutralize WNV poorly in vitro, yet 
still can protect mice from WNV infection (55). Here, we examined in greater detail the 
ability of two DII-FL MAbs, E53 and E28, to inhibit infection in vitro and in vivo. These 
DII-FL MAbs neutralized WNV differentially according to the cell type used and the 
maturity of the virus stock, with fully mature WNV more resistant to neutralization. The 
DII-FL MAbs protected wild type mice from lethal WNV infection, and prophylaxis with 
E28 MAb decreased WNV viremia at days one and two after infection and reduced 
infection in the brain at seven days after infection. The protective activity of DII-FL 
MAbs was essentially abolished in mice lacking both C1q and FcγR or in wild type mice 
treated with an aglycosyl MAb variant, establishing that Fc effector functions mediate in 
vivo protection of poorly neutralizing MAbs. While studies with deficient mice and 
depleting antibodies indicated that B, T, and NK cells were not necessary for this 
protection, phagocytes were required. Cross-reactive polyclonal antibodies from DENV 
immune hamsters and humans also were poorly neutralizing against WNV in vitro and 
directed against the DII-FL epitope. Nonetheless, and analogous to data with E28 MAb, 
these cross-reactive polyclonal antibodies conferred protection in passive transfer studies 
in mice.   
Using multiple in vitro assays with WNV derived from different cell sources, we 
confirmed the poorly neutralizing capacity of DII-FL MAbs against WNV. While the 
PRNT assay on BHK21-15 or Vero cells remains the “gold standard” measure of 
antibody neutralization of flaviviruses (61), imperfect correlations between titers in vitro 
and protection in vivo have been observed (9). One hypothesis as to why poorly 
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neutralizing antibodies protect in vivo is that the PRNT assay, which is usually performed 
with C6/36-cell derived viral stocks, does not account for the inherent neutralizing 
activity of all classes of antibody against flaviviruses. To determine whether the source of 
the WNV stock affected MAb inhibitory activity by PRNT assay, we tested WNV 
prepared in mammalian Vero cells or in vivo from the plasma of mice. Plasma rather than 
serum-derived WNV was used to avoid maturation artifacts associated with ex vivo 
activation of clotting cascade serine proteases, which might adventitiously cleave prM. 
Vero cell and plasma derived WNV was essentially mature and resistant to DII-FL MAb 
neutralization by PRNT assay, consistent with studies showing DII-FL MAbs poorly bind 
or neutralize mature forms of WNV (13, 51). 
Because a prior study suggested differential inhibitory activity of anti-WNV 
MAbs mapping to DI and DII using RVP and Raji-DCSIGN-R cells (55), we expanded 
our analysis to determine whether poor neutralizing activity of MAbs showed cell type-
specific effects. E28 did not neutralize insect or mammalian cell-derived WNV in Raji-
DCSIGN-R cells; indeed, it paradoxically enhanced infection through an unknown 
mechanism as these cells lack expression of activating Fc-γR. Therefore Raji-DCSIGN-R 
cells were not inherently better than BHK21-15 cells at revealing the neutralization 
potential of E28. However, when less mature forms of RVP were prepared, E28 showed 
modest inhibitory activity on Raji-DCSIGN-R cells, analogous to that described with E53 
(51). Thus, the neutralization capacity of DII-FL MAbs was cell type and maturation 
state-dependent, and the PRNT assay provided an incomplete evaluation of the inherent 
inhibitory activity of these antibodies. This idea is important to consider, as the humoral 
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response to vaccines against WNV (1) and DENV (49) is evaluated primarily using the 
PRNT assay. 
The results of the cell culture studies suggested that DII-FL MAbs, such as E28, 
were at most weakly neutralizing and possibly non-neutralizing depending on the source 
of virus and assay used for evaluation. Nonetheless, E28 and other poorly neutralizing 
DII-FL MAbs were protective in passive transfer experiments in mice (55). The ability of 
poorly neutralizing MAbs to protect animals against virus infection is not inherently 
novel, as it has been observed with flaviviruses (27, 34, 55), alphaviruses (10, 38, 46, 66), 
coronaviruses (50), reoviruses (76), and rhabdoviruses (37). These studies were 
observational, however, and the mechanism of protection in animals remained 
uncharacterized. Based on its in vitro properties, we selected E28 for an in-depth analysis 
of the mechanism of protection in mice. Studies with both strongly and poorly 
neutralizing antibodies against herpesviruses (81), flaviviruses (65), retroviruses (32, 47), 
and poxviruses (7) established that Fc effector functions were required for reducing viral 
burden and clinical morbidity. Analogously, our passive transfer experiments with C1q-/- 
x FcγR-/- mice or an aglycosyl E28 variant in wild type mice demonstrate the necessity of 
Fc effector functions for protection by weakly or non-neutralizing antibodies.  
As the Fc portion of an antibody can engage complement and FcγRs, we repeated 
infections in C1q-/-, FcγR-/-, and C1q-/- x FcγR-/- mice to gain further mechanistic insight 
into protective mechanisms. While some protective capacity was lost in C1q-/- mice, E28 
and E53 failed to protect C1q-/- x FcγRIII-/- mice, implicating this FcγR as a key 
component of the survival phenotype conferred by poorly neutralizing MAbs. How do Fc 
effector functions enhance the protective potential of weakly neutralizing antibodies? As 
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a previous study had demonstrated that C5 was not required for protective antibody 
effects on WNV (44), virion lysis appeared an unlikely mechanism. However, DII-FL 
MAbs may become neutralizing in the presence of C1q, as it reduces the stoichiometric 
threshold required for antibody neutralization (45). Further mechanistic studies were 
aimed at identifying the cell type(s) in vivo that conferred the protective activity. As E28 
still decreased viremia in WNV infected RAG1-/- mice, it seems unlikely that immune 
complex uptake, enhanced antigen presentation, and priming of the adaptive B and T cell 
responses explained the protective effects in vivo. The experiments in RAG1-/- mice were 
supported by prophylaxis studies with E53 showing no change in the kinetics of CD4+ or 
CD8+ T cell activation or quality of the neutralizing antibody response after WNV 
infection in wild type mice (M. Vogt and M. Diamond, unpublished studies). 
Although NK cells appear unnecessary for protection against primary WNV 
infection in mice (68), those studies were performed in naïve animals, which lack pre-
existing anti-WNV antibodies. As our passive transfer experiments suggested that 
FcγRIII contributed to E28-mediated protection, and NK cell ADCC requires FcγRIII 
(62), it seemed plausible that NK cells might be required for the survival benefit 
conferred by E28. However, mice depleted of NK cells showed no significant change in 
E28-mediated protection compared to those receiving an isotype control, non-depleting 
MAb. This was supported by evidence that E28 does not protect C1q-/- x FcγRI-/- mice 
from WNV infection (Table S1). These mice presumably have functional FcγRIII on 
their NK cells, and their NK cells were not sufficient for E28-mediated protection. 
As complement and FcγRs also can promote phagocytosis of antibody-opsonized 
antigens, we speculated that a specific cell type capable of phagocytosis of viral particles 
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or infected cells conferred E28-mediated protection. After non-selectively depleting 
phagocytes from wild type mice with clodronate containing liposomes, E28 no longer 
reduced WNV viremia during the first two days of infection. Since clodronate-containing 
liposomes deplete several cell types with phagocytic potential (78), we tested the role of 
specific populations of phagocytes by antibody depletion. Gr-1 is expressed on 
neutrophils and inflammatory monocytes (21), both of which have phagocytic potential. 
As E28 MAb prophylaxis retained its ability to decrease viremia in mice treated with 
depleting concentrations of anti-Gr-1 antibody, neutrophils and inflammatory monocytes 
were likely not the key phagocytic cell types that conferred protection. While additional 
experiments are needed to absolutely identify the target cell type, our data collectively 
suggests that a complement and FcγR-expressing innate immune phagocyte (e.g., tissue 
macrophage or activated dendritic cell) mediates protection of E28 in mice.   
While the detailed studies with E28 were informative from a mechanistic 
standpoint, it was important to confirm whether poorly neutralizing polyclonal antibodies 
shared the same phenotype. Purified polyclonal IgG from the serum of DENV-immune 
hamsters was E28-like, as it recognized SVP in a capture ELISA, was specific largely for 
the DII-FL epitope on WNV E protein, and was poorly neutralizing in both PRNT and 
RVP assays. Analogously, these cross-reactive polyclonal antibodies nonetheless 
protected wild type mice from WNV infection. The anti-WNV antibody repertoire in 
many human patients is skewed similarly toward the DII-FL epitope (54, 75), which is 
somewhat surprising given that MAbs recognizing this epitope neutralize WNV poorly 
and do not bind fully mature virus (51). In screening sera from humans with a remote 
history of DENV infection, a single prior exposure elicited a minor cross-reactive 
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antibody response, whereas individuals with evidence of multiple heterotypic infections 
perhaps unsurprisingly elicited higher titers of WNV reactive antibodies (M. Vogt and M. 
Diamond, unpublished results), which neutralized WNV poorly and bound the DII-FL 
epitope. The similarity of the DENV immune human sera to the protective hamster IgG 
suggests that immunodominant DII-FL antibodies elicited in response to natural DENV 
infection (16), while non-neutralizing against WNV and undetected by the PRNT assay, 
could still confer protection via Fc effector function mechanisms. While further 
epidemiologic studies are warranted, widespread exposure to DENV and other endemic 
flaviviruses in tropical America could result in production of polyclonal DII-FL-specific 
antibodies that fail to neutralize WNV infection by conventional PRNT analysis but still 
protect humans in vivo, and thus contribute to the lack of severe cases of human WNV 
infection in this region. Indeed, one recent serological surveillance study in Mexico 
supports this hypothesis (63). 
Overall this study describes a mechanism for the protective effects in vivo of anti-
WNV antibodies that are poorly neutralizing by in vitro assays. For WNV, both MAbs 
and polyclonal antibodies directed against the DII-FL epitope protected wild type mice 
from lethal WNV infection in vivo. This activity was dependent upon the Fc effector 
functions of the antibodies, and required phagocytic cells, C1q and FcγRIII. The ability 
of cross-reactive antibodies elicited by heterologous flavivirus infection to protect against 
WNV in vivo could explain the fewer than anticipated number of reported cases of WNV 
infection in Central and South America, and analogously, the historical observation of 
reduced numbers of SLEV or JEV infections in DENV-immune regions of the Americas 
and Southeast Asia (11, 31). Finally, the inability of the PRNT assay to predict the 
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functional capacity of specific classes of protective anti-flavivirus antibodies should give 
pause to its use as the definitive assay for measuring the immune response to the 
multitude of flavivirus vaccines that are in clinical testing or under development. 
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TABLE 1. MAb protection of 4 to 5 week-old wild type mice 
MAb Epitope 
on 
WNV E 
Isotype Neutralizing 
activity 
MTD + 
SDa 
Survival 
(%) 
P value 
PBS - - - 10.1 + 2.1 8 of 57  
(14%) 
- 
Control 
MAb 
(DENV2-
E70, anti-
DENV E) 
- IgG1 - 10.2 + 2.1 4 of 20 
(20%) 
0.6 
Control 
MAb 
(2H2 
anti-
DENV 
prM) 
- IgG2a - 10.2 + 1.6 3 of 30 
(10%) 
0.9 
E24 DIII-LR IgG2a +++ 15 28 of 29 
(97%) 
< 
0.0001 
E28 DII-FL IgG1 - 11.1 + 3.1 24 of 40 
(60%) 
< 
0.0001 
E34 DIII-LR IgG1 +++ 12 9 of 10 
(90%) 
< 
0.0001 
E53 DII-FL IgG2a + 10.4 + 1.9 13 of 30 
(43%) 
0.003 
 
 
Four to five week-old wild type mice were passively transferred 40 µg of the indicated 
MAbs one day prior to infection with 102 PFU of C6/36 cell-derived WNV. Survival 
analysis was followed for 21 days and P values were determined using the log rank test 
as compared to PBS-treated mice. The isotype control MAbs react specifically with 
DENV but not WNV proteins (data not shown). Neutralization activity was scored 
according to data in Fig 1A:  +++, strong neutralization; +, partial neutralization; and -, 
no neutralization. The epitope location on WNV E protein is based on prior published 
studies (53, 55). 
a  Mean time to death + standard deviation of the mice that succumbed to infection. 
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TABLE 2. MAb protection of 8 to 12 week-old mice lacking antibody effector 
functions 
 
A. C1q-/- mice 
MAb Dose (µg) Epitope 
on 
WNV E 
Isotype MTD + 
SDa 
Survival 
(%) 
P value 
PBS - - - 11.0 + 0.6 5 of 12 
(42%) 
- 
Control 
MAb 
(DENV2-
E70, anti-
DENV E) 
40 - IgG1 11.4 + 1.7 6 of 16 
(38%) 
0.9 
Control 
MAb 
(2H2 
anti-
DENV 
prM) 
400 - IgG2a 12.0 + 2.3 3 of 8 
(38%) 
0.9 
E24 40 DIII-LR IgG2a N.A. 12 of 12 
(100%) 
0.002 
E24 400 DIII-LR IgG2a N.A. 11 of 11 
(100%) 
0.003 
E28 40 DII-FL IgG1 14.0 + 2.0 7 of 10 
(70%) 
0.11 
E34 40 DIII-LR IgG1 17 8 of 9 
(89%) 
0.02 
E53 40 DII-FL IgG2a 13.0 + 2.0 8 of 11 
(73%) 
0.09 
E53 400 DII-FL IgG2a 16 9 of 10 
(90%) 
0.02 
 
 
B. FcγR-/- 
MAb Dose (µg) Epitope 
on 
WNV E 
Isotype MTD + 
SDa 
Survival 
(%) 
P value 
PBS - - - 10.6 + 2.0 3 of 15 
(20%) 
- 
Control 
MAb 
40 - IgG1 11.4 + 1.6 1 of 9 
(11%) 
0.9 
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(DENV2-
E70, anti-
DENV E) 
Control 
MAb 
(2H2 
anti-
DENV 
prM) 
400 - IgG2a 12.3 + 3.6 5 of 12 
(42%) 
0.3 
E24 40 DIII-LR IgG2a N.A. 10 of 10 
(100%) 
0.0001 
E24 400 DIII-LR IgG2a N.A. 11 of 11 
(100%) 
< 
0.0001 
E28 40 DII-FL IgG1 12.5 + 1.0 7 of 11 
(64%) 
0.008 
E34 40 DIII-LR IgG1 N.A. 5 of 5 
(100%) 
0.006 
E53 40 DII-FL IgG2a 11.8 + 1.6 4 of 10 
(40%) 
0.16 
E53 400 DII-FL IgG2a 9.8 + 1.0 8 of 12 
(67%) 
0.04 
 
 
C. C1q-/- x FcγR-/- 
MAb Dose (µg) Epitope 
on 
WNV E 
Isotype MTD + 
SDa 
Survival 
(%) 
P value 
PBS - - - 11.2 + 1.1 1 of 25 
(4%) 
- 
Control 
MAb 
(DENV2-
E70, anti-
DENV E) 
40 - IgG1 11.8 + 1.6 2 of 17 
(12%) 
0.1 
Control 
MAb 
(2H2 
anti-
DENV 
prM) 
400 - IgG2a 11.0 + 2.0 1 of 10 
(10%) 
0.5 
E24 40 DIII-LR IgG2a 16.0 + 2.6 14 of 17 
(82%) 
< 
0.0001 
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E24 400 DIII-LR IgG2a N.A. 11 of 11 
(100%) 
< 
0.0001 
E28 40 DII-FL IgG1 13.1 + 2.2 1 of 15 
(7%) 
0.01 
E28 400 DII-FL IgG1 12.8 + 1.8 0 of 8 
(0%) 
0.09 
E34 40 DIII-LR IgG1 15.0 + 5.7 8 of 10 
(80%) 
< 
0.0001 
E53 40 DII-FL IgG2a 12.9 + 2.2 0 of 10 
(0%) 
0.08 
E53 400 DII-FL IgG2a 12.9 + 3.1 0 of 8 
(0%) 
0.4 
 
 
D. C1q-/- x FcγRIII-/- 
MAb Dose (µg) Epitope 
on 
WNV E 
Isotype MTD + 
SDa 
Survival 
(%) 
P value 
PBS - - - 11.8 + 2.6 13 of 25 
(52%) 
- 
Control 
MAb 
(DENV2-
E70, anti-
DENV E) 
40 - IgG1 12.0 + 4.6 4 of 8 
(50%) 
> 0.9 
E24 40 DIII-LR IgG2a N.A. 5 of 5 
(100%) 
0.07 
E28 40 DII-FL IgG1 11.3 + 3.1 6 of 16 
(38%) 
0.3 
E53 40 DII-FL IgG2a 13.0 + 3.3 16 of 24 
(67%) 
0.3 
 
Eight to twelve week-old mice were passively transferred PBS or the indicated MAbs one 
day prior to infection with 102 PFU of C6/36 cell-derived WNV. Survival was followed 
and P values were determined using the log rank test compared to PBS-treated mice. 
N.A. indicates not applicable as none of the animals succumbed to infection. 
a  Mean time to death + standard deviation of the mice that succumbed to infection. 
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TABLE S1. MAb protection of 8 to 12 week-old C1q-/- x FcγRI-/- mice 
MAb Dose (µg) Epitope 
on 
WNV E 
Isotype MTD + 
SDa 
Survival 
(%) 
P value 
PBS - - - 11.4 + 1.4 3 of 10 
(30%) 
- 
Control 
MAb 
(DENV2-
E70, anti-
DENV E) 
40 - IgG1 12.3 + 2.4 4 of 11 
(36%) 
0.6 
E34 40 DIII-LR IgG1 N.A. 5 of 5 
(100%) 
0.02 
E28 40 DII-FL IgG1 13.4 + 1.8 7 of 17 
(41%) 
0.2 
E53 40 DII-FL IgG2a 11.9 + 1.5 2 of 9 
(22%) 
> 0.9 
 
Eight to twelve week-old mice were passively transferred PBS or the indicated MAbs one 
day prior to infection with 102 PFU of C6/36 cell-derived WNV. Survival analysis was 
followed for 21 days and P values were determined using the log rank test compared to 
PBS-treated mice. N.A. indicates not applicable as none of the animals succumbed to 
infection. 
a  Mean time to death + standard deviation of the mice that succumbed to infection. 
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FIGURE LEGENDS 
 Figure 1. Neutralizing activity of MAbs in cell culture against different 
preparations of WNV. A, E, and F. PRNT assay. E28 (DII-FL, IgG1), E53 (DII-FL, 
IgG2a), E24 (DIII-LR, IgG2a), and E34 (DIII-LR, IgG1) were tested for neutralization of 
(A) C6/36 cell, (E) Vero cell or (F) plasma-derived WNV (50 to 125 PFU) by classical 
PRNT assay on BHK21-15 cells. Data shown are combined results of two independent 
experiments in triplicate. The data is normalized to data from six control wells in each 
experiment with no MAb. B. RVP neutralization assay on Raji-DCSIGN-R cells. E28 
was incubated with RVP prior to infection of Raji-DCSIGN-R cells. RVP were prepared 
normally (mixture of mature, immature, and partially mature) or in cells over-expressing 
the furin protease (mature) to create a more homogeneous population of mature virions. 
The data shown are the combined results of three independent experiments performed in 
duplicate, and the results are normalized to that from two control wells in each 
experiment with no MAb. C. WNV neutralization assay on Raji-DCSIGN-R cells. WNV 
(MOI of 0.001) derived from C6/36 cells, Vero cells, or plasma of infected AG129 mice 
was mixed with medium (DMEM) or 30 µg/ml of MAbs E24 or E28 prior to infection of 
Raji-DCSIGN-R cells. One day later, cells were stained with Ch-E16 and processed by 
flow cytometry. The data shown are representative of three independent experiments 
performed in triplicate, and are normalized to that from three control wells for each virus 
with no MAb. D. A Western blot with anti-E (top) or anti-prM/M (bottom) antibodies 
using WNV derived from C6/36 cells, Vero cells, or plasma from infected AG129 mice. 
For anti-E blot, an equivalent number of PFU were loaded as judged by plaque assay on 
BHK21-15 cells. G. Inhibition of WNV replication by MAbs in multi-step growth 
analysis. C6/36 cell-derived WNV was mixed with medium (DMEM) or 30 µg/ml of 
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MAbs E24 or E28 prior to infection of BHK21-15 cells. At the indicated time points, 
supernatant was harvested for titration by plaque assay. Data shown are combined data 
from three independent experiments performed in triplicate.  
 Figure 2. Protective effect of E28 MAb in mice. A. WNV burden in the serum of 
5 week-old wild type C57BL/6 mice that were administered PBS or E28 (40 µg) via an 
intraperitoneal route one day prior to WNV infection (C6/36 cell-derived, 102 PFU) via a 
subcutaneous route. At the indicated days, serum was harvested and viral burden was 
determined by qRT-PCR assay. The data is expressed as genome equivalents per ml of 
serum and reflects 8 to 20 animals per condition per time point. Asterisks indicate values 
that are statistically significant (**, P < 0.01; ***, P < 0.001). B. WNV burden in the 
brain of 5 week-old wild type mice. Mice were treated as described above. At days 5 or 7 
after WNV infection, brains were harvested and viral burdens were determined by plaque 
assay on BHK21-15 cells. The data is expressed as PFU per gram and reflects 8 to 10 
animals per condition per time point. The following percentage of mice had viral burdens 
below detection (< 65 PFU/g): day 5, PBS - 0%; E28 – 40%; day 7, PBS – 0%; E28 – 
25%. Asterisks indicate values that are statistically significant (*, P < 0.05). All analysis 
utilized the Mann-Whitney non-parametric t test.  
 Figure 3. Efficacy of different anti-WNV MAbs in C1q-/- and FcγR-/- mice. Eight 
to twelve week-old (A) C1q-/-, (B) FcγR-/-, or (C) C1q-/- x FcγR-/- C57BL/6 mice were 
passively transferred 40 µg of E24 (DIII-LR, IgG2a), E34 (DIII-LR, IgG1), E53 (DII-FL, 
IgG2a), E28 (DII-FL, IgG1), an isotype control (IgG1), or PBS one day prior to infection 
with 102 PFU of C6/36 cell-derived WNV. Animals were followed for survival over a 
period of three weeks. The number of animals for each antibody condition ranged as 
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follows: C1q-/-: 9 to 16; FcγR-/-: 5 to 15; and C1q-/- x FcγR-/-: 8 to 25. Statistically 
significant differences are described in the text and were compared to the PBS treated 
mice. 
 Figure 4. Functional activity of wild type or aglycosyl chimeric E28 MAbs in 
vitro and in vivo. A. A capture ELISA was used to detect binding of wild type or N297Q 
Ch-E28 MAbs to WNV SVP. Microtiter plates were coated with murine E24, incubated 
with SVP, and detected with increasing concentrations of the indicated chimeric (Ch-
E28, N297Q Ch-E28, or Ch-E16) or control human IgG1 antibodies. One representative 
of three independent experiments is shown. B. PRNT assay. Ch-E28 and N297Q Ch-E28 
were tested for neutralization of C6/36 cell-derived WNV by standard PRNT assay on 
BHK21-15 cells. Data shown are combined results of two independent experiments in 
triplicate. The data is normalized to data from six control wells in each experiment with 
no MAb. C. Four week-old wild type C57BL/6 mice were passively transferred PBS or 
40 µg of Ch-E28 or N297Q Ch-E28E24 one day prior to infection with 102 PFU of C6/36 
cell-derived WNV. Animals were followed for survival over a period of three weeks. The 
number of animals for each antibody condition ranged from 13 to 19. Asterisks indicate 
values that are statistically significant by the log rank test (*, P < 0.05). D. WNV burden 
in the brain of 4 week-old wild type mice. Mice were treated as described above. At day 
7 after WNV infection, brains were harvested and viral burdens were determined by 
plaque assay on BHK21-15 cells. The data is expressed as PFU per gram and reflects 22 
animals per condition. The following percentage of mice had viral burdens below 
detection (< 100 PFU/g): PBS - 14%; Ch-E28 – 59%; N297Q Ch-E28 – 36%. Asterisks 
indicate values that are statistically significant by a one-way ANOVA (**, P < 0.01). The 
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viral burden between Ch-E28 and N297Q Ch-E28 approached statistical significance (P 
= 0.05). 
 Figure 5. Protective effect of E28 MAb in RAG1-/- mice. WNV burden in the 
serum of eight to twelve week-old congenic RAG1-/- C57BL/6 mice that were 
administered E28 (500 µg) or an isotype control MAb via an intraperitoneal route one 
day prior to WNV infection (C6/36 cell-derived, 1 PFU) via a subcutaneous route. At the 
indicated days, serum was harvested and viral burden was determined by qRT-PCR 
assay. The data is expressed as genome equivalents per ml of serum and reflects 5 to 10 
animals per condition per time point. Asterisks indicate values that are statistically 
significant by the Mann-Whitney non-parametric t test (**, P < 0.01, ***, P < 0.001).  
 Figure 6. Effect of depletion of NK cells on protective activity of E28 MAb. NK 
cells were depleted from wild type mice after treatment with anti-NK1.1 antibody (100 
µg) 2 days before and after infection with WNV. A. Depletion of NK cells was confirmed 
by flow cytometry after staining with anti-NKp46 and anti-CD3. B. WNV infection of 
NK cell-depleted mice. Sixteen wild type mice (five week-old) were treated with either 
anti-NK1.1 or an isotype control antibody (2H2, anti-DENV prM), administered E28 (40 
µg), infected with WNV (C6/36 cell-derived, 102 PFU) and monitored for survival. No 
statistically significant differences in mortality were observed by the log rank test (P > 
0.6). 
 Figure 7. Effect of depletion of phagocytes and neutrophils on protective activity 
of E28 MAb. Eight to twelve week-old wild type mice were administered E28 (500 µg) 
or an isotype control MAb via an intraperitoneal route one day prior to WNV infection 
(C6/36 cell-derived, 1 PFU) via a subcutaneous route. A-B. Depletion of phagocytes with 
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clodronate-containing liposomes. A. (Left) Gating strategy of CD11b+ and CD45+ cells 
by flow cytometry. (Right) Quantitative depletion of CD11b+ and CD45+ phagocyte cell 
populations in the spleen of RAG1-/- mice by clodronate liposomes. Depletion with 
clodronate-containing liposomes reduced the number of CD45intCD11bhi and 
CD45hiCD11bint by 74% and 91%, respectively. B Effect of clodronate or PBS liposomes 
on E28-mediated reduction in viremia. Wild type mice were treated with clodronate- or 
PBS-containing liposomes one day prior to and after infection with WNV. At the 
indicated days, serum was harvested and viral burden was determined by qRT-PCR 
assay. The data is expressed as genome equivalents per ml of serum and reflects 8 
animals per condition per time point. Asterisks indicate values that are statistically 
significant (**, P < 0.01). C-D. Effect of depletion of neutrophils and inflammatory 
monocytes on protective activity of E28 MAb. Neutrophils and inflammatory monocytes 
were depleted from wild type mice after treatment with anti-Gr-1 antibody (250 µg) one 
day before infection with WNV. C. Depletion of neutrophils and inflammatory 
monocytes was confirmed by flow cytometry after staining with anti-Ly6C and Ly6G. D. 
Effect of neutrophil and inflammatory monocyte depletion on E28-mediated reduction in 
viremia. At day 2 after infection, serum was harvested and viral burden was determined 
by qRT-PCR assay. The data is expressed as genome equivalents per ml of serum and 
reflects 8 animals per condition per time point. Asterisks indicate values that are 
statistically significant (*, P < 0.05; ***, P < 0.001). All analyses utilized the Mann-
Whitney test. 
 Figure 8. Functional activity in vitro and in vivo of polyclonal IgG derived from 
naïve or DENV-2 infected hamsters. A. A capture ELISA was used to detect binding of 
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naive or DENV-2 immune polyclonal IgG to WNV SVP. Microtiter plates were coated 
with murine E24, incubated with SVP, and detected with increasing concentrations of the 
indicated affinity-purified polyclonal hamster IgG. One representative of three 
independent experiments is shown. B. PRNT assay. Naive and DENV-2 immune 
polyclonal IgG were tested for neutralization of C6/36 cell-derived WNV by PRNT assay 
on BHK21-15 cells. Data shown are combined results of two independent experiments 
performed in triplicate. The data is normalized to data from six control wells in each 
experiment with no MAb. C. RVP neutralization assay on Raji-DCSIGN-R cells. 
Increasing concentrations of naive or DENV-2 immune polyclonal IgG were incubated 
with RVP for one hour prior to infection of Raji-DCSIGN-R cells. RVP were prepared 
normally (mixture of mature, immature, and partially mature) or in cells over-expressing 
the furin protease (mature) to create virions of different maturation states. Data shown are 
representative results of two independent experiments performed in duplicate. D. Epitope 
specifity of DENV-2 immune hamster IgG against WNV E protein. Comparison of 
antibody titer from DENV-2 immune hamster for wild type (E-WT) and DII-FL loss-of-
function variants (E-W101R and E-quadruple (Quad) mutant). Titers of antibodies were 
compared from individual DENV-2 infected hamsters. Note, the plating density of E-WT, 
E-W101R, and E-quadruple mutant was equivalent as no difference in binding was 
observed with E24 (DIII-LR) MAb when tested in parallel (data not shown). Asterisks 
indicate values that are statistically significant by the student’s paired t test (**, P < 
0.01). E. Four to five week-old wild type C57BL/6 mice were passively transferred PBS 
or 400 µg of pooled naïve or DENV-2 immune affinity-purified IgG one day prior to 
infection with 102 PFU of C6/36 cell-derived WNV. Animals were followed for survival 
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over a period of three weeks. The number of animals for each condition ranged from 10 
to 15. Asterisks indicate values that are statistically significant by the log rank test (*, P < 
0.05).  
 Figure 9. Sera from humans with a history of multiple DENV infections contain 
cross-reactive, poorly neutralizing antibodies directed against the DII-FL epitope. The 
cross-reactivity of these human immune sera for DENV is described in the Materials and 
Methods. A. Epitope specificity of DENV immune human serum against WNV E protein. 
Comparison of antibody titer from DENV immune human serum for wild type (E-WT) 
and DII-FL loss-of-function variants (E-W101R and E-quadruple (Quad) mutant). Note 
the plating density of E-WT, E-W101R, and E-quadruple mutant was equivalent as no 
difference in binding was observed with Ch-E16 (DIII-LR) MAb when tested in parallel 
(data not shown). Asterisks indicate values that are statistically significant by the 
student’s paired t test (*, P < 0.05; **, P < 0.01). B. WNV PRNT assay. DENV immune 
human sera from six individuals with a history of heterotypic infections was tested for 
neutralization of C6/36 cell-derived WNV by PRNT assay on BHK21-15 cells. Data 
shown are combined results of two independent experiments performed in triplicate. The 
data is normalized to data from 12 control wells in each experiment with naïve human 
serum. 
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Conclusions  
Prior to this thesis, extensive work had characterized the neutralizing antibody 
response to WNV. E protein reactive antibodies were determined immunodominant in the 
neutralizing response (4, 39), and the characteristics of antibodies binding to many 
specific epitopes on the E protein were defined (1, 6, 11, 27, 29, 33). MAbs binding to 
the DIII-LR epitope were consistently the most strongly neutralizing antibodies. These 
antibodies neutralize mature and immature virions equally (25), require only a small 
fraction of their available epitopes to be bound within a specific virion to eliminate 
infectivity (15, 26, 31), and function by steric inhibition of the pH-dependent E protein 
rearrangement necessary for fusion of the virion with the late endosomal membrane (26, 
36). The neutralizing antibody repertoire of WNV-infected mice was dominantly directed 
toward the DIII-LR epitope, however studies with sera from convalescent WNV infected 
humans revealed that few neutralizing antibodies were directed toward this epitope (28). 
The absence of the most strongly neutralizing antibodies was surprising, as the antibody 
response is necessary for the resolution of WNV infection (7, 8), ~80% of human 
infections are asymptomatic (22), and the antibody response is protective against 
secondary challenge (7). A further unexpected result of these human studies was that the 
DII-FL epitope was immunodominant in WNV convalescent sera (28), as MAbs directed 
to this epitope fail to recognize fully mature WNV virions efficiently (25) and 
accordingly neutralize infection poorly in vitro (29). The work in this thesis was aimed at 
determining the significance of this apparent discrepancy between the ability of a 
polyclonal antibody repertoire consisting primarily of poorly neutralizing antibodies to 
efficiently limit the pathogenesis of WNV infection in vivo. 
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The first approach undertaken in this thesis challenged the assumption that the 
human antibody repertoire was poorly neutralizing. We hypothesized that strongly 
neutralizing antibodies were indeed generated, but were directed to cryptic epitopes on 
the E protein or non-E epitopes that went undetected based on limitations of the epitope 
based diagnostics used. This seemed likely because the WNV virion is composed of 90 E 
dimers, and each E protein exists in one of three different symmetry environments (23), 
none of which are likely present in recombinant protein ELISA assays used to quantify 
epitope specificity (28). This led us to characterize in detail two WNV-specific human 
MAbs, CR4348 and CR4354. These MAbs were isolated from B cell populations of 
convalescent patients by screening for binding to different forms of WNV antigen (37). 
Both MAbs strongly neutralized WNV infection of cultured cells and protected mice 
against lethal infection in vivo, yet they poorly recognized recombinant forms of E 
protein. Instead, we found that CR4348 and CR4354 bound determinants on intact WNV 
virions and subviral particles in a pH-sensitive manner, and neutralization was altered by 
mutations at the dimer interface in domain II and the hinge between domains I and II, 
respectively. CR4348 and CR4354 human MAbs neutralized infection at a post-
attachment step in the viral lifecycle, likely by inhibiting acid-induced fusion within the 
endosome. Further studies with CR4354 determined that neutralization was not 
dependent upon bivalency of the MAb. Collaborators utilized cryo-electron microscopy 
(EM) of virions saturated with CR4354 Fab fragments to confirm binding to the DI-DII 
hinge epitope. These studies identified a novel mechanism of neutralization: tethering 
together E proteins from different symmetry environments to prevent the dissociation of 
E dimers necessary for fusion (16). 
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Based on historical examples of the ability of antiviral antibodies that neutralize 
poorly in vitro to protect against infection in animals (2, 10, 14, 18, 19, 21, 24, 29, 34, 
38), the second approach of this thesis was to study the functional properties in vivo of 
the immunodominant but poorly neutralizing DII-FL antibodies. We showed that while 
passive transfer of poorly neutralizing MAbs and polyclonal antibodies against the DII-
FL epitope protect against lethal WNV infection in wild type mice, they fail to protect 
mice lacking activating FcγRs and the complement opsonin C1q. Consistent with this, an 
aglycosyl chimeric mouse-human DII-FL MAb (E28) variant that lacked the ability to 
engage FcγR and C1q also did not protect against WNV infection in wild type mice. 
Using a series of immunodeficient mice and antibody depletions of individual immune 
cell populations, we demonstrated that the non-neutralizing DII-FL MAb E28 did not 
require T, B, or NK cells, inflammatory monocytes, or neutrophils for in vivo protection. 
Rather, E28 MAb treatment decreased viral load in the serum early in the course of 
infection, which resulted in blunted dissemination to the brain, an effect that required 
phagocytic cells, C1q and FcγRIII (CD16). Finally, we demonstrated that human and 
hamster polyclonal antibody responses after DENV infection that cross-react with WNV 
are generally poorly neutralizing and skewed to the DII-FL epitope, and that passive 
transfer of IgG purified from DENV-immune hamsters also protected mice from lethal 
WNV infection. 
The work in this thesis highlights the neutralization potential of antibodies not 
accounted for by current diagnostic assays and enhances our understanding of the 
functional significance of immunodominant poorly-neutralizing antibodies in the 
polyclonal human anti-flavivirus response. These studies underscore the limitations of 
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many common applications of in vitro assays: the initial identification of antiviral MAbs 
by their ability to bind to non-native viral antigens and the usage of surrogate markers of 
protection such as cell-based neutralization assays as the definitive assay for measuring 
the immune response to vaccines. Finally, this work could explain the low number of 
infections by flaviviruses of the JEV serocomplex (WNV, JEV, and SLEV) in regions of 
the world with a high prevalence of DENV immunity (3, 12, 17, 30) due to Fc-mediated 
protection by cross-reactive poorly-neutralizing DII-FL antibodies, which may escape 
detection in conventional neutralization tests. 
 
Future Directions  
The studies with human MAbs CR4348 and CR4354 presented strong evidence 
for their epitopes localizing to the DII dimer interface and DI-DII hinge interface, 
respectively, but lacked definitive proof. Two structural approaches to determine 
antibody epitopes are co-crystallization with antigen for x-ray crystallography and 
binding to virions at saturating concentrations for cryo-EM, both utilizing Fab fragments 
to eliminate confounding structural mobility. Our collaborators performed cryo-EM 
studies with CR4354 Fab fragments, confirming that it binds to the DI-DII hinge epitope 
(16). Each asymmetric unit on the pseudo-icosahedral surface of the WNV virion 
contains three E proteins, one in each symmetry environment (2-, 3-, and 5-fold axes of 
symmetry) (23). The CR4354 Fab bound at two E proteins within the asymmetric unit 
(120 total sites per virion). Interetsingly,, the Fab electron density was observed over the 
DI-DII hinge of E in one environment as well as over sites in DIII of E in a second 
environment (16). This suggested that CR4354 may function to lock neighboring E 
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proteins together, thereby preventing the dissociation of E protein dimers at low pH in the 
late endosome to prevent fusion and infection. Unexpected results also were obtained in a 
separate study using similar methods to observe the binding of neutralizing 1A1D-2 Fab 
to DENV-2 virions, which trapped the virion in a different structural configuration (20). 
While we hypothesize that CR4348 binds across E protein dimers, definitive cryo-EM 
studies are required to establish a structural mechanism of inhibition.  
Another alternative for epitope confirmation is to co-crystallize recombinant E 
protein with Fab fragments of CR4348 and CR4354. One potential complication to these 
studies is the monomeric nature of WNV E, both in solution and in crystals (13, 26), and 
neither of these human MAb appreciably bound to purified protein. Nonetheless, it 
remains possible that the addition of Fab to WNV E under crystallization conditions 
could drive dimer formation, especially with CR4348 Fab, which likely binds across the 
E dimer on the virion surface. 
Even if strongly neutralizing MAbs that bind to CR4348 or CR4354-like epitopes 
are a significant part of the human repertoire, antibodies binding to these epitopes may go 
undetected using existing methods for defining the repertoire of antibodies in WNV 
convalescent humans (28). This indicates a need for new approaches to define the 
antibody repertoire of WNV immune humans with assays capable of detecting these 
epitopes. Although the methodology of measuring binding titers by ELISA to wild type 
antigen and quantitating the loss of binding to mutant antigen can still be utilized, in 
parallel, experiments with wild type or variant intact virions or subviral particles appear 
to be required.  
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Any new studies of the human antibody repertoire should also include a 
comparison of people who experienced asymptomatic versus symptomatic WNV 
infection. Since ~80% of humans do not experience any signs or symptoms of infection 
(22), studies with convalescent sera may not be representative of the typical human 
antibody response. This could explain the observed predominance of poorly neutralizing 
DII-FL antibodies, as these measurements could have focused on an ineffective repertoire 
of antibodies. People with asymptomatic infections are frequently identified in screenings 
of blood donors in WNV endemic areas, and cohorts of these individuals have been 
identified. Studies of the anti-E antibody repertoire of their sera may reveal that the 
majority of humans actually generate a more effective antibody response against strongly 
neutralizing epitopes. 
The studies in this thesis showing an Fc dependent mechanism of protection 
against WNV infection by poorly neutralizing DII-FL MAb E28 provide a deeper 
understanding of the importance of these antibodies within the polyclonal immune 
repertoire. However, further studies are needed to define these Fc effector mechanisms 
more specifically. We have identified phagocytes as the cell type that contributes most to 
this effect. While many cells have phagocytic capacity, macrophages seem likely to 
mediate FcγR-dependent protection in vivo based on the following lines of evidence: 
macrophages do not not express Gr-1; FcγRI, FcγRIII and likely complement receptors, 
which are all expressed by macrophages, are necessary for protection; and clodronate 
liposomes treatment depleted CD45+CD11b+ cells. The classic macrophage deficient 
op/op mouse strain, which does not produce macrophage colony stimulating factor, is 
technically challenging because these osteopetrotic mice have myriad health concerns 
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(40), which would complicate the interpretation of their response to WNV infection. 
However, a new strain of op/op mice with restored osteoclast function could be a useful 
model to investigate the necessity of macrophages for E28 MAb mediated protection 
from WNV. 
Antibodies that bind the DII-FL epitope are highly cross-reactive among 
flaviviruses (5, 6, 9, 29). The ability of DII-FL antibodies to protect against WNV led us 
to hypothesize a role for immunity generated against DENV infection in protecting 
humans from infection by viruses in the JEV serocomplex. Historically, areas of high 
DENV prevalence in Southeast Asia and the Americas have experienced low levels of 
infection by SLEV and JEV (3, 12). This could explain why WNV spread so rapidly 
through the United States and into Canada, yet has failed to expand cause human disease 
in Mexico, Central and South America despite the migration of birds that harbor WNV 
into these areas and appropriate mosquito vectors for transmission (17, 30). Further 
epidemiologic studies are warranted to define whether the inverse relationship between 
DENV and WNV prevalence in Latin America is dependent upon pre-existing DII-FL 
antibodies elicited by DENV infection. One such recent, large scale study in northern 
Mexico supports our hypothesis, although it did not test the epitope specificity of the 
potentially protective cross-reactive antibodies (32). Further, if DENV elicited DII-FL 
antibodies can indeed protect from infection by JEV serocomplex viruses, these 
antibodies may affect the immunogenicity of any attenuated vaccine strains. Existing JEV 
and even more distantly related YFV vaccine strains could be used to challenge DENV 
immune and naive individuals to observe for effects of cross-reactive antibodies. Finally, 
the ability of hamsters to elicit predominantly DII-FL antibodies in response to flavivirus 
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infection indicates they are a possible alternative model to mice for the study of flavivirus 
infection, especially for studies of the humoral immune response. 
An interesting observation of the in vitro activities of E28 with WNV in cell 
culture is that this MAb was capable of both neutralization and enhancement of infection. 
E28 MAb poorly neutralized RVP, but in the PRNT assay with C6/36 and Vero cell-
derived WNV it subtly enhanced infection; E28 markedly enhanced infection with 
plasma-derived WNV in the PRNT assay, which utilizes BHK21-15 cells, and with all 
WNV sources on Raji-DCSIGN-R cells. We have preliminary data that another anti-E 
MAb, E87, enhances C6/36 cell-derived WNV infection in the PRNT assay (Fig 1A) and 
in multi-step growth analysis (Fig 1B). Classical antibody-dependent enhancement 
(ADE) of infection in vitro is a reasonably well understood phenomenon, one involving 
the infection of FcγR bearing cells (35). However, the experiments with E28 and E87 
used BHK21-15 cells, which lack expression of FcγRs. To further confirm FcγR-
independence, F(ab’)2 fragments could be used in vitro. As with E28, E87 prophylaxis of 
mice also protected from WNV infection (Fig 1C), so any potential enhancing effects of 
these MAbs in vivo may be overcome by their protective Fc effector functions. 
Therefore, further study of FcγR-independent ADE is unlikely to provide insight on the 
natural course of WNV infection. Nonetheless, these studies are warranted as  
understanding the mechanism of FcγR-independent ADE in cell culture could increase 
our comprehension of the step(s) in the viral life cycle that are affected, especially if they 
were coupled with structural studies. One hypothesis that is intriguing is that some of 
these MAbs could trap WNV in a conformational state that is more infectious, either by 
enhancing attachment or entry or by stabilizing virus from degradation. Alternatively, 
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MAbs of this class could enhance infectivity by promoting formation of immune 
complexes and/or viral aggregates.   
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FIGURE LEGEND 
 Figure 1. Effects of E87 MAb on WNV infection in vitro and in vivo. A. 
PRNT assay. Dilutions of E87 MAb were incubated with C6/36 cell-derived WNV for 
one hour at 37°C, then added to a monolayer of BHK21-15 cells for one hour at 37°C, 
then overlaid with agarose-containing medium and incubated at 37°C for 3 days before 
fixation with 10% formaldehyde and visualization of plaques by staining with crystal 
violet. Data shown are from a single experiment in triplicate. The data is normalized to 
data from three control wells with no MAb. B. Multi-step growth analysis. C6/36 cell-
derived WNV was mixed 1:1 with medium (DMEM) or hybridoma supernatants of 
MAbs E85 or E87 for one hour at 37°C prior to infection of BHK21-15 cells at a MOI of 
0.01. At the indicated time points, supernatant was harvested for titration by plaque 
assay. Data shown are from a single experiment. C. Effect of E87 prophylaxis in wild 
type mice. Five week old C57BL/6 mice were passively transferred 400 μg of E87 (n=10) 
or PBS (n=32) one day prior to infection with 102 PFU of C6/36 cell-derived WNV. 
Animals were followed for survival over a period of three weeks. Survival curves were 
significantly different as determined by the log rank test (P = 0.0005). 
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Appendix A 
 
Development of Resistance to Passive Therapy with a Potently Neutralizing 
Humanized Monoclonal Antibody against West Nile Virus  
 
This chapter is reprinted essentially as published in The Journal of Infectious Diseases. 
 
Shuliu Zhang*, Matthew R. Vogt*, Theodore Oliphant, Michael Engle, Evgeniy I. 
Bovshik, Michael S. Diamond, and David W. C. Beasley. Journal of Infectious Diseases. 
2009. 200 (2): 202-5. 
 
*These authors contributed equally to the study. 
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INTRODUCTION 
West Nile virus (WNV) is a mosquito-borne flavivirus that has emerged as the 
primary cause of epidemic encephalitis in the United States.  Although case numbers 
have declined somewhat since the peak activity of 2002 and 2003, virus transmission 
continues throughout the continental United States and thousands of cases of neurological 
disease have been reported each year since 2004.  At present there is no WNV vaccine or 
antiviral therapy approved for use in humans, although promising treatment results were 
observed in case reports using purified immunoglobulin derived from Israeli donors [1, 
2]. 
The potential of passive immunotherapy for treatment of WNV infection has led 
to the development and evaluation of potently neutralizing human or humanized mouse 
monoclonal antibodies (MAbs) [3, 4].  One therapeutic candidate, humanized E16 
(hE16), binds to a highly conserved epitope on the upper lateral ridge of WNV envelope 
(E) protein domain III (E-DIII) and neutralizes WNV at low stoichiometric occupancy, 
apparently by inhibiting conformational changes in E that are required for fusion of the 
virus with host cell membranes [3, 5, 6].  However, mapping studies by several groups 
have identified mutations in the hE16 epitope that significantly reduce or abolish binding 
of this and other neutralizing WNV MAbs [3, 7-9]. A few of these mutations are found in 
WNV strains isolated in the field [8], suggesting that the efficacy of hE16 could be 
limited.  Furthermore, flaviviruses have error-prone genome replication, resulting in 
significant genetic diversity within any individual isolate. Indeed, this property has been 
used as the basis for in vitro selection of variants resistant to a particular selective 
pressure, such as that imposed by antiviral inhibitors or neutralizing MAbs.  The potential 
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for in vivo selection of MAb-resistant variants of flaviviruses has not yet been examined 
in detail.   
In this study, we assessed (1) the potential for WNV strains encoding engineered 
mutations in the hE16 binding site to resist passive immunotherapy with hE16 in two 
mouse models of WNV neuroinvasive disease, and (2) the potential for neutralization-
resistant variants to be selected in vivo during hE16 treatment. 
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MATERIALS AND METHODS 
All WNV strains and infectious clone-derived variants used in this study (Table 1 
and Results) were grown and plaque titrated on Vero cells.  Neutralization assays were 
performed on Vero or BHK-21 cells, as described elsewhere [3].  RNA extractions, 
reverse-transcription polymerase chain reaction, and nucleotide sequencing of the pre-
membrane (prM) and E coding regions of WNV genomes were performed using 
protocols and primers that have been described elsewhere [7].  
 Swiss Webster mice (female; 3-4 weeks of age) were obtained from Harlan 
Laboratories, and wild type and congenic RAG C57BL/6 mice (female; 5 weeks of age) 
were obtained from The Jackson Laboratory.  All mice were housed in animal biosafety 
level 3 facilities accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care International, and experiments were conducted under protocols 
approved by the Animal Care and Use Committee of the University of Texas Medical 
Branch or Washington University School of Medicine.  Details of individual passive-
protection experiments are described below. 
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RESULTS 
Previous crystallographic and epitope mapping studies have suggested that hE16 
has key contacts at residues 307, 330, and 332 of the WNV E protein [3, 5].  The ability 
of hE16 to neutralize selected WNV strains and NY99 infectious clone-derived variants 
encoding single amino acid changes at these residues was initially assessed by a plaque 
reduction neutralization assay on Vero cells.  These viruses have been shown to variably 
escape neutralizing MAbs [7, 8].  Notably, only the mutation T332K resulted in a 
substantial loss of hE16 neutralizing activity, whereas other mutations (K307R, T330I, 
T332A/M) showed only modest changes in neutralization compared to the wild-type 
lineage 1 NY99 virus (Fig 1A).  Lineage 2 South African strain H442 (SA58), isolated in 
1958 from a human patient, normally encodes a lysine at residue 332 and has been 
reported to be resistant to neutralization by several E-DIII-reactive antibodies raised 
against NY99 [7]; this virus was also resistant to neutralization by hE16, whereas an 
SA58 variant encoding threonine at 332 [7] was efficiently neutralized (Fig 1B). 
Two independent mouse challenge models were used to assess the protection 
provided by hE16 against the neutralization-sensitive and neutralization-resistant WNV 
strains and variants.  Groups of outbred Swiss Webster mice, which are highly 
susceptible to peripheral challenge with neuroinvasive WNV strains, were given 100 µg 
doses of hE16 or phosphate-buffered saline (PBS) only and challenged 24 hours later 
with 102 plaque forming units (PFU) of each WNV strain/variant (equivalent to ~100 
LD50s in each case).  Alternatively, groups of inbred C57BL/6 mice, which are more 
resistant to WNV NY99 and have been used in previous evaluations of hE16 [3, 10] were 
challenged with 102 PFU of each virus and treated at two days after infection with 100 µg 
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hE16 or PBS only.  The hE16 MAb afforded significant protection (90-100% survival) 
for mice in either the pre- or postexposure model against NY99 and variants that were 
efficiently neutralized in vitro by hE16 (TR330I and T332A/M).  However, little or no 
protection was observed after challenge with the NY99ic T332K mutant or SA58 (Table 
1).   
Although mutagenesis of an infectious clone or in vitro selection can readily 
generate viruses resistant to hE16 and other MAbs, we questioned whether this 
commonly occurred under selective pressure during the course of treatment. To assess the 
potential for selection of resistant variants in vivo during MAb treatment, Swiss Webster 
mice pre-treated with 100 µg hE16 were exposed to a high dose (104 PFU) of NY99 
virus. This challenge dose was chosen based on the known frequency of MAb escape 
variants selected from this virus population during earlier experiments [7] and because 
this represents a virus dose reliably introduced during feeding by Culex. mosquitoes [11].  
All untreated control animals died by day 9 after infection (average survival time 7.4±1.0 
days).  Two of 10 treated mice showed signs of neuroinvasive disease and were 
euthanized on days 8 and 9.  Virus was isolated from the brain of each mouse, and the 
isolates were found to encode single-nucleotide changes in E coding for mutation K307E 
and T332M. Both isolates retained the highly neuroinvasive phenotype of the parental 
NY99 virus (data not shown). 
Immune dysfunction is a significant risk factor for development of severe WNV 
disease [reviewed in 12], suggesting that therapeutic antibodies and other treatments may 
be especially important for immunodeficient patients.  To assess the potential for 
emergence of resistant variants during treatment of an immunocompromised host, a 
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group of 30 B and T cell-deficient RAG mice was exposed to a low dose (102 PFU) of 
strain WNV-NY2000 (3000-0259), which has an E gene sequence identical to that of 
NY99 [13], and then treated with 500 µg doses of hE16 administered one day after 
infection and at 14 day intervals thereafter.  Although 24 mice remained healthy over a 
period of several months, six mice became ill and were either found dead or euthanized 
on days 18 (2 mice), 20 (2 mice), 32 (1 mouse) and 34 (1 mouse).  Brains recovered from 
the latter two mice each yielded WNV encoding the K307E E protein mutation. 
Consistent with previous studies [3], the recovered K307E variants were resistant 
to in vitro neutralization (Fig 1C) or in vivo protection (Table 1) by hE16, whereas the 
recovered T332M variant was only modestly resistant to E16 neutralization in vitro (data 
not shown) or in vivo (Table 1), similar to the NY99ic T332M variant.   
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DISCUSSION 
The use of polyclonal or monoclonal immunotherapy is currently being explored 
for treatment of infections caused by many families of viruses and clearly offers a 
promising approach for postexposure treatment of flavivirus infections.  In the case of 
hE16 for treatment of WNV infection, the presence of naturally occurring mutations in 
some WNV strains at the MAb binding site suggests that treatment coverage will not be 
universal, as evidenced by the resistance of lineage 2 strain SA58 in vitro and in vivo.  
Nonetheless, hE16 still afforded strong protection against variants encoding other 
mutations that increased resistance to neutralization but did not abolish binding.  Analysis 
of more than 650 derived amino acid sequences in the NCBI Protein database 
representing human, avian, equine or mosquito North American WNV isolates during 
1999-2005 identified none with amino acid variation at positions 307, 330, or 332, which 
could impair hE16 recognition and neutralization. 
The present studies have also demonstrated the potential for in vivo selection of 
MAb escape variants.  Although surprisingly infrequent, in vivo resistance may occur via 
selection of a pre-existing mutant subpopulation following exposure to higher doses of 
virus, a phenomenon which has also recently been reported in passively immunized 
monkeys exposed to 106 PFU doses of dengue virus type 2 [14]. Alternatively, resistance 
can develop through the emergence of variant viruses during prolonged treatment.  
The length of time required for the emergence of the resistant K307E variants 
following 102 PFU challenge in RAG mice (up to 34 days) compared with the rapid 
selection of variants from the 104 PFU challenge in Swiss Webster mice (8-9 days), was 
somewhat surprising.  Based on the inherent error rate of the flavivirus RNA polymerase 
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(~1 mutation per genome replication), the occurrence of resistant mutations at the genetic 
level should be expected to occur rapidly. The delay in emergence of resistance in RAG 
mice could be explained by packaging of early variant genomes in virions that also 
contain levels of wild-type E protein sufficient to allow neutralization by hE16. This is 
possible because flavivirus RNA can be encapsidated by structural proteins in trans [15] 
and complete neutralization (>99%) of WNV virions by hE16 requires occupancy of less 
than 50% of the available epitopes [6]. Although further studies are necessary, high levels 
of circulating hE16 with a long half-life may adequately neutralize virions comprised of 
wild type and resistant E protein variants to prevent rapid or eventual emergence of 
pathogenic escape variants, even in a highly immunocompromised subject. 
Overall, these findings suggest that resistance to neutralizing anti-WNV antibody 
therapy can occur in vivo, although at frequencies that are perhaps lower than would be 
anticipated based on analogous studies of resistance to antiviral drugs that target virus 
replication. However, our data suggest that clinical evaluation of hE16 and other MAb 
therapeutics for flavivirus infections should monitor for selection or emergence of 
resistant variants, especially in immunocompromised patients, who are a likely target 
population for treatment of severe WNV infections.  Such studies should include 
characterization of viral populations for detection of resistance and possibly the use in 
some patients of combinations of neutralizing antibodies that recognize distinct epitopes. 
  
179 
TABLE 1. Outcomes of infections of mice with West Nile virus strains or variants 
after  pre- or post-exposure treatment with the neutralizing MAb hE16. 
 
   hE16 treated PBS only  
Mouse 
strain 
hE16 
Treatment* Virus 
% 
survivors AST±sd† 
% 
survivors AST±sd 
Survival 
P value‡ 
Swiss 
Webster 
100µg day 
-1 
NY99 
wt 100 n/a 20 8.4±1.2 0.0003 
  NY99ic T332A 100 n/a 10 8.1±0.3 <0.0001
  NY99ic T332M 90 8.0±0.0 0 8.4±0.8 <0.0001
  NY99ic T332K 30 7.4±0.8 10 8.8±1.5 0.8984 
  NY99ic T330I 90 8.0±0.0 0 7.8±0.4 0.0008 
  SA58 0 7.2±0.4 0 7.5±0.5 0.1704 
  SA58 K332T 100 n/a 0 7.5±0.7 <0.0001
        
C57BL/6 100µg day +2 
NY99ic 
wt 100 n/a 30 11.0±1.7 <0.0001
  NY99ic T332A 100 n/a 20 9.3±1.9 0.0003 
  NY99ic T332M 100 n/a 30 10.7±1.6 <0.0001
  NY99ic T330I 100 n/a 10 9.4±1.8 <0.0001
  SA58 10 10.8±1.6 0 9.3±1.1 0.0207 
  SA58 K332T 100 n/a 10 10.2±1.4 <0.0001
        
Swiss 
Webster 
100µg day 
-1 
NY99 
K307E 10 8.8±1.3 0 7.8±0.4 0.0773 
  NY99 
T332M 
70 13.3±3.8 0 8.0±0.7 0.0001 
 
* Swiss Webster mice were treated with 100µg hE16 or PBS only, then challenged 1 day 
later with 100 PFU of indicated WNV strains (1000 pfu for NY99ic T332K).  C57BL/6 
mice were inoculated with 100 PFU of indicated WNV strains, then treated 2 days later 
with 100 µg hE16 or with PBS only.  n=10 for each virus/treatment group, except for 
NY99 K307E/T332M “PBS only” groups, where n=5. 
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† AST – average survival time; sd – standard deviation; n/a – not applicable 
‡ Significant differences in survival curves for hE16 treated vs. PBS only groups 
determined by log rank test using the Prism application (Graphpad Software). 
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FIGURE LEGEND 
Figure 1.  Neutralization by MAb hE16 of: (A) lineage 1 WNV strain NY99ic 
and K307R, T330I and T332A/K/M variants; (B) lineage 2 WNV strain SA58 and 
K332T variant; and (C) K307E escape variants selected in vivo from hE16-treated RAG 
mice. The data are an average of two to four independent experiments performed in 
triplicate on (A, B) Vero or (C) BHK21-15 cells.  
FIGURE 1. 
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